

Severely Suppressed Bone Turnover: A Potential Comp

Journal of Clinical Endocrinology and Metabolism
90, 1294-1301

DOI: [10.1210/jc.2004-0952](https://doi.org/10.1210/jc.2004-0952)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 2 | Drug-induced bone disease. Adverse Drug Reaction Bulletin, 2005, &NA;, 903-906. | 0.6 | 0 |
| 3 | Alendronate (Fosamax) and Risedronate (Actonel) Revisited. Obstetrics and Gynecology, 2005, 106, 402-404. | 1.2 | 2 |
| 4 | The use of bisphosphonates in the treatment of osteoporosis. Current Opinion in Internal Medicine, 2005, 4, 512-516. | 1.5 | 43 |
| 5 | Bisphosphonate therapy for the treatment of postmenopausal osteoporosis. Aging Health, 2005, 1, 459-474. | 0.3 | 1 |
| 6 | Manipulation of the Anabolic and Catabolic Responses With OP-1 and Zoledronic Acid in a Rat Critical Defect Model. Journal of Bone and Mineral Research, 2005, 20, 2044-2052. | 3.1 | 125 |
| 7 | Treatment of osteoporosis in old age. Reviews in Clinical Gerontology, 2005, 15, 83-90. | 0.5 | 1 |
| 8 | Osteoporosis and Integrins. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2466-2468. | 1.8 | 28 |
| 9 | Treatment of Paget's Disease " Taming the Wild Osteoclast. New England Journal of Medicine, 2005, 353, 872-875. | 13.9 | 26 |
| 10 | Managing the care of patients with bisphosphonate-associated osteonecrosis. Journal of the American Dental Association, 2005, 136, 1658-1668. | 0.7 | 378 |
| 11 | Serum Tartrate-Resistant Acid Phosphatase 5b or Amino-Terminal Propeptide of Type I Procollagen for Monitoring Bisphosphonate Therapy in Postmenopausal Osteoporosis?. Clinical Chemistry, 2005, 51, 2382-2385. | 1.5 | 10 |
| 12 | Long-Term Safety of Bisphosphonates. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1897-1899. | 1.8 | 201 |
| 13 | Available medical choices for the management of menopause. Maturitas, 2005, 52, 61-70. | 1.0 | 13 |
| 14 | Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochemical and Biophysical Research Communications, 2005, 338, 710-716. | 1.0 | 57 |
| 15 | A rational approach to evidence gaps in the management of osteoporosis. American Journal of Medicine, 2005, 118, 1183-1189. | 0.6 | 18 |
| 16 | Osteonecrosis of the Jaw and Bisphosphonates. New England Journal of Medicine, 2005, 353, 99-102. | 13.9 | 648 |
| 17 | Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws. Annals of Internal Medicine, 2006, 144, 753. | 2.0 | 1,105 |
| 18 | Long-Term Safety of Bisphosphonate Therapy for Osteoporosis. Drugs and Aging, 2006, 23, 289-298. | 1.3 | 25 |
| 19 | Emerging Issues With Bisphosphonates. Rheumatic Disease Clinics of North America, 2006, 32, 691-702. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 20 | Effect of systemic glucocorticoid therapy on bone metabolism: an update. Expert Review of Endocrinology and Metabolism, 2006, 1, 111-122. | 1.2 | 0 |
| 21 | Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncology, The, 2006, 7, 508-514. | 5.1 | 311 |
| 23 | Lessons from osteoporosis clinical trials. , 2006, 2, 155-159. | | 2 |
| 24 | Prevention of Bone Necrosis in Patients with Cancer. Supportive Cancer Therapy, 2006, 3, 183-186. | 0.3 | 0 |
| 25 | Optimising Antiresorptive Therapies in Postmenopausal Women. Drugs, 2006, 66, 1909-1918. | 4.9 | 35 |
| 26 | Investigation of cardiac status and bone mineral density in Turner syndrome. Growth Hormone and IGF Research, 2006, 16, 103-108. | 0.5 | 14 |
| 27 | Strontium ranelate: A physiological approach for optimizing bone formation and resorption. Bone, 2006, 38, 10-14. | 1.4 | 164 |
| 28 | Bone Quality – The Material and Structural Basis of Bone Strength and Fragility. New England Journal of Medicine, 2006, 354, 2250-2261. | 13.9 | 1,687 |
| 29 | Bisphosphonates. Arquivos Brasileiros De Endocrinologia E Metabologia, 2006, 50, 735-744. | 1.3 | 17 |
| 30 | Low-Molecular-Weight Heparin and Bleeding: How Do We Lower Risk but Maintain Benefit?. Annals of Internal Medicine, 2006, 145, 789. | 2.0 | 3 |
| 31 | Health Insurance Portability and Accountability Act Privacy Rule and Research Consent Documents. Annals of Internal Medicine, 2006, 145, 790. | 2.0 | 1 |
| 32 | Bone quality: what is it and how is it measured?. Arquivos Brasileiros De Endocrinologia E Metabologia, 2006, 50, 579-585. | 1.3 | 89 |
| 33 | Withholding Resuscitation: A New Approach to Prehospital End-of-Life Decisions. Annals of Internal Medicine, 2006, 145, 788. | 2.0 | 1 |
| 34 | Beneficial Effect of Oral Bisphosphonate Treatment on Bone Loss Induced by Chronic Administration of Furosemide without Alteration of Its Administration and Urinary Calcium Loss. Clinical Pediatric Endocrinology, 2006, 15, 101-107. | 0.4 | 4 |
| 35 | Regional Variations in Health Care Intensity and Physicians' Perceptions of Care Quality. Annals of Internal Medicine, 2006, 145, 788. | 2.0 | 2 |
| 36 | Maintaining bone health in patients with prostate cancer. Medical Journal of Australia, 2006, 184, 176-179. | 0.8 | 24 |
| 37 | Prevention of osteoporotic fractures. Aging Health, 2006, 2, 649-659. | 0.3 | 0 |
| 38 | Use of generic alendronate in the treatment of osteoporosis. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2006, 11, 46-50. | 0.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 39 | Osteonecrosis of the jaw. <i>Current Opinion in Orthopaedics</i> , 2006, 17, 462-468. | 0.3 | 6 |
| 40 | Management of osteoporosis in postmenopausal women. <i>Menopause</i> , 2006, 13, 340-367. | 0.8 | 180 |
| 41 | Osteoporosis therapy. <i>Current Opinion in Orthopaedics</i> , 2006, 17, 451-455. | 0.3 | 1 |
| 42 | Bone disease in idiopathic hypercalciuria. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 394-402. | 1.0 | 70 |
| 43 | Current, new and emerging anti-resorptive drugs; antibody blockade of RANKL action. <i>BoneKEY Osteovision</i> , 2006, 3, 42-46. | 0.6 | 1 |
| 44 | Current advances in research that affect patient care. <i>International Journal of Dental Hygiene</i> , 2006, 4, 106-108. | 0.8 | 0 |
| 46 | Bisphosphonates: From Bench to Bedside. <i>Annals of the New York Academy of Sciences</i> , 2006, 1068, 367-401. | 1.8 | 344 |
| 47 | Effects of Anticatabolic and Anabolic Therapies at the Tissue Level. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2006, 4, 177-196. | 1.3 | 1 |
| 49 | Sacral insufficiency fractures: current concepts of management. <i>Osteoporosis International</i> , 2006, 17, 1716-1725. | 1.3 | 132 |
| 50 | Osteoporosis prevention and therapy: preserving and building strength through bone quality. <i>Osteoporosis International</i> , 2006, 17, 1707-1715. | 1.3 | 34 |
| 51 | Osteopenia and osteoporosis in patients with HIV: A review of current concepts. <i>Current Infectious Disease Reports</i> , 2006, 8, 162-170. | 1.3 | 33 |
| 52 | Bone integrity and bone metastases in breast cancer. <i>Current Oncology Reports</i> , 2006, 8, 22-28. | 1.8 | 6 |
| 53 | Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats. <i>BMC Musculoskeletal Disorders</i> , 2006, 7, 63. | 0.8 | 37 |
| 54 | Osteoporosis: How Should it be Treated?. <i>Journal of Investigative Medicine</i> , 2006, 54, 114-122. | 0.7 | 5 |
| 55 | Long-Term Use of Bisphosphonates in Osteoporosis. <i>Women's Health</i> , 2006, 2, 309-315. | 0.7 | 2 |
| 57 | Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis. <i>New England Journal of Medicine</i> , 2006, 355, 2048-2050. | 13.9 | 100 |
| 58 | The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 870-877. | 1.8 | 37 |
| 59 | Clinical value of the biochemical markers of bone remodeling in the assessment of bone metabolic diseases. <i>Journal of Medical Biochemistry</i> , 2006, 25, 241-248. | 0.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 60 | Glucocorticoids suppress bone formation via the osteoclast. <i>Journal of Clinical Investigation</i> , 2006, 116, 2152-2160. | 3.9 | 330 |
| 61 | Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2006, 22, 919-928. | 0.9 | 46 |
| 62 | Dental management of patients receiving oral bisphosphonate therapy. <i>Journal of the American Dental Association</i> , 2006, 137, 1144-1150. | 0.7 | 250 |
| 63 | THANKS TO AAOM: Author's response. <i>Journal of the American Dental Association</i> , 2006, 137, 440-441. | 0.7 | 0 |
| 64 | MORE ABOUT BON. <i>Journal of the American Dental Association</i> , 2006, 137, 441. | 0.7 | 1 |
| 65 | RANK ligand inhibition with denosumab for the management of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1041-1050. | 1.4 | 47 |
| 66 | Weekly alendronate versus risedronate for postmenopausal osteoporosis—is there a difference?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 90-91. | 2.9 | 0 |
| 67 | Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 686-687. | 2.9 | 3 |
| 68 | Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 42-55. | 4.3 | 111 |
| 69 | Bisphosphonate-associated osteonecrosis of the jaw. <i>Menopause International</i> , 2007, 13, 56-59. | 1.6 | 5 |
| 70 | Periodontal Diseases and Rheumatoid Arthritis: A Coincident Model for Therapeutic Intervention?. <i>Current Drug Metabolism</i> , 2007, 8, 750-757. | 0.7 | 26 |
| 71 | Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1601-1607. | 0.4 | 27 |
| 72 | Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1283-1288. | 1.8 | 119 |
| 73 | Update in Osteoporosis and Metabolic Bone Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 747-753. | 1.8 | 84 |
| 74 | The anabolic and catabolic responses in bone repair. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2007, 89-B, 425-433. | 3.4 | 108 |
| 75 | The effects of short-term hormone replacement therapy on long-term bone mineral density. <i>Climacteric</i> , 2007, 10, 257-263. | 1.1 | 16 |
| 77 | New mechanisms and targets in the treatment of bone fragility. <i>Clinical Science</i> , 2007, 112, 77-91. | 1.8 | 46 |
| 78 | A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics. <i>Clinical Therapeutics</i> , 2007, 29, 1548-1558. | 1.1 | 253 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 79 | Bisphosphonates and Bisphosphonate Induced Osteonecrosis. Oral and Maxillofacial Surgery Clinics of North America, 2007, 19, 487-498. | 0.4 | 34 |
| 80 | Serum Osteoprotegerin Concentration with Strontium Ranelate Treatment for Postmenopausal Osteoporosis: An Open, Prospective Study. Current Therapeutic Research, 2007, 68, 217-225. | 0.5 | 0 |
| 81 | Jaw osteonecrosis related to bisphosphonate therapy. Bone, 2007, 40, 828-834. | 1.4 | 97 |
| 82 | A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone, 2007, 40, 1222-1230. | 1.4 | 85 |
| 83 | A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone, 2007, 40, 1238-1243. | 1.4 | 104 |
| 84 | Effect of combined humanPTH(1-34) and calcitonin treatment in ovariectomized rats. Bone, 2007, 41, 786-793. | 1.4 | 22 |
| 85 | Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment. Journal of Oral and Maxillofacial Surgery, 2007, 65, 2397-2410. | 0.5 | 630 |
| 86 | Osteoclasts: What Do They Do and How Do They Do It?. American Journal of Pathology, 2007, 170, 427-435. | 1.9 | 603 |
| 87 | Postmenopausal osteoporosis: an update on current and future therapeutic options. Expert Review of Endocrinology and Metabolism, 2007, 2, 79-90. | 1.2 | 0 |
| 88 | Osteonecrosis of the jaw and bisphosphonates: A comparison with white phosphorus, radium, and osteopetrosis. Clinical Toxicology, 2007, 45, 753-762. | 0.8 | 12 |
| 89 | Subtrochanteric insufficiency fractures in patients on alendronate therapy. Journal of Bone and Joint Surgery: British Volume, 2007, 89-B, 349-353. | 3.4 | 448 |
| 90 | Effect of Long-Term Oral Bisphosphonates on Implant Wound Healing: Literature Review and a Case Report. Journal of Periodontology, 2007, 78, 584-594. | 1.7 | 121 |
| 91 | Osteonecrosis of the Jaws and Bisphosphonate Therapy. Journal of Dental Research, 2007, 86, 1013-1021. | 2.5 | 128 |
| 92 | Bisphosphonates: Mode of Action and Pharmacology. Pediatrics, 2007, 119, S150-S162. | 1.0 | 411 |
| 93 | Looking beyond low bone mineral density: Multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. Journal of Endocrinological Investigation, 2007, 30, 590-597. | 1.8 | 52 |
| 94 | Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis. Drug Safety, 2007, 30, 755-763. | 1.4 | 111 |
| 95 | Avalia o do efeito do ibandronato na consolida o de fratura: estudo experimental em coelhos. Revista Brasileira De Ortopedia, 2007, 42, 254-260. | 0.2 | 1 |
| 96 | High Concentrations of Pamidronate in Bone Weaken the Mechanical Properties of Intact Femora in a Rat Model. Yonsei Medical Journal, 2007, 48, 653. | 0.9 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 97 | Antiresorptive agents and osteoclast apoptosis. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 1087-1096. | 1.2 | 31 |
| 98 | Quelle est la durée optimale des traitements dans l'ostéoporose postménopausique?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 27-34. | 0.0 | 4 |
| 99 | Is There a Role for Bisphosphonates in Chronic Kidney Disease?. <i>Seminars in Dialysis</i> , 2007, 20, 186-190. | 0.7 | 67 |
| 100 | Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. <i>Journal of Oral Pathology and Medicine</i> , 2007, 36, 319-328. | 1.4 | 66 |
| 101 | Novel host response therapeutic approaches to treat periodontal diseases. <i>Periodontology 2000</i> , 2007, 43, 294-315. | 6.3 | 145 |
| 102 | Bone turnover 18 months after a single intravenous dose of zoledronic acid. <i>International Journal of Clinical Practice</i> , 2007, 61, 1058-1062. | 0.8 | 18 |
| 103 | The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. <i>BMC Musculoskeletal Disorders</i> , 2007, 8, 3. | 0.8 | 46 |
| 104 | Eating disorders in the 21st century: identification, management, and prevention in obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2007, 21, 331-343. | 1.4 | 17 |
| 105 | How long should patients take medications for postmenopausal osteoporosis?. <i>Joint Bone Spine</i> , 2007, 74, 24-31. | 0.8 | 36 |
| 106 | Picking a bone with contemporary osteoporosis management: Nutrient strategies to enhance skeletal integrity. <i>Clinical Nutrition</i> , 2007, 26, 193-207. | 2.3 | 24 |
| 107 | Comment on the American Association of Oral and Maxillofacial Surgeons Statement on Bisphosphonates. <i>Journal of Oral and Maxillofacial Surgery</i> , 2007, 65, 1440-1441. | 0.5 | 10 |
| 108 | Bisphosphonates. <i>Annals of the New York Academy of Sciences</i> , 2007, 1117, 209-257. | 1.8 | 341 |
| 109 | Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1502-1509. | 3.1 | 135 |
| 110 | Bisphosphonate treatment: An orthodontic concern calling for a proactive approach. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2007, 131, 311-320. | 0.8 | 66 |
| 111 | Combination therapy for treatment of osteoporosis: A review. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 559-565. | 0.7 | 24 |
| 112 | Sequential Treatment with Intermittent Low-Dose Human Parathyroid Hormone (1-34) and Bisphosphonate Enhances Large-Size Skeletal Reconstruction by Vascularized Bone Transplantation. <i>Calcified Tissue International</i> , 2007, 81, 232-239. | 1.5 | 18 |
| 113 | Temporal progression of skeletal cystic angiomas. <i>Skeletal Radiology</i> , 2007, 36, 1199-1204. | 1.2 | 15 |
| 114 | Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents. <i>Osteoporosis International</i> , 2007, 18, 569-573. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 115 | Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats. <i>Osteoporosis International</i> , 2007, 18, 1531-1540. | 1.3 | 8 |
| 116 | Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 7, 101-112. | 2.6 | 24 |
| 117 | Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. <i>Journal of Bone and Mineral Metabolism</i> , 2007, 25, 333-336. | 1.3 | 42 |
| 118 | Over-suppression of bone turnover: Does it exist?. <i>Current Osteoporosis Reports</i> , 2007, 5, 179-185. | 1.5 | 5 |
| 119 | New directions in osteoporosis therapy: Intravenous ibandronate and denosumab. <i>Current Rheumatology Reports</i> , 2007, 9, 47-49. | 2.1 | 2 |
| 120 | Bisphosphonate-induced Osteonecrosis of the Jaws: Review, Clinical Implications and Case Report. <i>Head and Neck Pathology</i> , 2007, 1, 156-164. | 1.3 | 8 |
| 121 | (iv) Osteoporosis treatments and their effect on fracture healing. <i>Orthopaedics and Trauma</i> , 2008, 22, 336-340. | 0.3 | 6 |
| 122 | Fracture risk remains reduced one year after discontinuation of risedronate. <i>Osteoporosis International</i> , 2008, 19, 365-372. | 1.3 | 206 |
| 123 | Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. <i>Osteoporosis International</i> , 2008, 19, 339-348. | 1.3 | 65 |
| 124 | Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. <i>Osteoporosis International</i> , 2008, 19, 733-759. | 1.3 | 1,180 |
| 125 | The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. <i>Osteoporosis International</i> , 2008, 19, 1355-1361. | 1.3 | 28 |
| 126 | Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. <i>Osteoporosis International</i> , 2008, 19, 1613-20. | 1.3 | 121 |
| 127 | Intestinal hyperabsorption of calcium and low bone turnover in hypercalciuric postmenopausal osteoporosis. <i>Urological Research</i> , 2008, 36, 233-239. | 1.5 | 8 |
| 128 | Case Report of Spontaneous, Nonspinal Fractures in a Multiple Myeloma Patient on Long-term Pamidronate and Zoledronic Acid. <i>HSS Journal</i> , 2008, 4, 123-127. | 0.7 | 40 |
| 129 | Osteonecrosis of the jaws and bisphosphonates. <i>Current Osteoporosis Reports</i> , 2008, 6, 31-38. | 1.5 | 30 |
| 130 | Bone Disease and Idiopathic Hypercalciuria. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2008, 6, 82-94. | 1.3 | 1 |
| 131 | Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment. <i>Journal of Orthopaedic Science</i> , 2008, 13, 438-441. | 0.5 | 14 |
| 132 | Bisphosphonates and Chronic Kidney Disease. <i>Kidney</i> , 2008, 17, 119-121. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 133 | Release of Prostaglandin E ₁ from N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates by Bone Cells. <i>Macromolecular Bioscience</i> , 2008, 8, 599-605. | 2.1 | 23 |
| 134 | Uptake of calcium phosphate nanoshells by osteoblasts and their effect on growth and differentiation. <i>Journal of Biomedical Materials Research - Part A</i> , 2008, 87A, 418-428. | 2.1 | 16 |
| 135 | Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 826-836. | 3.1 | 527 |
| 136 | Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1304-1308. | 3.1 | 41 |
| 137 | Recovery of Trabecular and Cortical Bone Turnover After Discontinuation of Risedronate and Alendronate Therapy in Ovariectomized Rats. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1689-1697. | 3.1 | 44 |
| 138 | Bisphosphonate-Induced Osteopetrosis: Novel Bone Modeling Defects, Metaphyseal Osteopenia, and Osteosclerosis Fractures After Drug Exposure Ceases. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1698-1707. | 3.1 | 88 |
| 139 | Oral and dental adverse drug reactions. <i>Periodontology 2000</i> , 2008, 46, 9-26. | 6.3 | 21 |
| 140 | Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. <i>Oral Diseases</i> , 2008, 14, 277-285. | 1.5 | 107 |
| 141 | An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?. <i>Injury</i> , 2008, 39, 224-231. | 0.7 | 391 |
| 142 | The ovariectomized, mature rat model of postmenopausal osteoporosis: An assessment of the bone sparing effects of curcumin. <i>Phytomedicine</i> , 2008, 15, 1069-1078. | 2.3 | 75 |
| 143 | Role of serum P1NP measurement for monitoring treatment response in osteoporosis. <i>Biomarkers in Medicine</i> , 2008, 2, 495-508. | 0.6 | 16 |
| 144 | Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ásea y del Metabolismo Mineral. <i>Revista Clinica Espanola</i> , 2008, 208, 1-24. | 0.2 | 67 |
| 145 | Current and future treatments of bone metastases. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 609-627. | 1.0 | 14 |
| 146 | Biodistribution and Pharmacokinetic Studies of Bone-Targeting N-(2-Hydroxypropyl)methacrylamide Copolymer ¹⁸ F-Alendronate Conjugates. <i>Molecular Pharmaceutics</i> , 2008, 5, 548-558. | 2.3 | 96 |
| 147 | Bisphosphonates: how do they work?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 831-847. | 2.2 | 101 |
| 148 | Bone remodelling: its local regulation and the emergence of bone fragility. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 701-722. | 2.2 | 149 |
| 149 | The Osteoclast: Friend or Foe?. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2008, 3, 457-484. | 9.6 | 318 |
| 150 | Evidence-Based Osteoporosis Care. , 2008, , 1629-1649. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 151 | Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis. , 2008, , 1725-1742. | | 6 |
| 152 | Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. <i>Maturitas</i> , 2008, 60, 92-107. | 1.0 | 47 |
| 153 | Bone remodeling during fracture repair: The cellular picture. <i>Seminars in Cell and Developmental Biology</i> , 2008, 19, 459-466. | 2.3 | 705 |
| 154 | Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2008, 106, e18-e21. | 1.6 | 10 |
| 155 | Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. <i>Bone</i> , 2008, 42, 90-97. | 1.4 | 90 |
| 156 | Establishing a reference range for bone turnover markers in young, healthy women. <i>Bone</i> , 2008, 42, 623-630. | 1.4 | 130 |
| 157 | Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. <i>Bone</i> , 2008, 43, 653-662. | 1.4 | 143 |
| 158 | A probable case of oral bisphosphonate-associated osteonecrosis of the jaw and recovery with parathyroid hormone treatment. <i>Current Therapeutic Research</i> , 2008, 69, 356-362. | 0.5 | 15 |
| 159 | Newer therapies in osteoporosis. <i>Indian Journal of Rheumatology</i> , 2008, 3, 148-157. | 0.2 | 5 |
| 160 | Bisphosphonates: Mechanism of Action and Role in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1032-1045. | 1.4 | 1,146 |
| 161 | Adverse-effect profiles of bisphosphonates are largely determined by their route of administration. <i>Drugs and Therapy Perspectives</i> , 2008, 24, 23-26. | 0.3 | 0 |
| 162 | Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates. <i>Gynecological Endocrinology</i> , 2008, 24, 601-609. | 0.7 | 14 |
| 163 | Bone disease drug discovery: examining the interactions between osteoblast and osteoclast. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 239-251. | 1.5 | 7 |
| 164 | Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate. <i>New England Journal of Medicine</i> , 2008, 358, 1304-1306. | 13.9 | 465 |
| 165 | Modeling and Remodeling. , 2008, , 1-28. | | 16 |
| 166 | Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity â€” Observations in two elderly patients. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 251-254. | 1.8 | 5 |
| 167 | Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 491-512. | 1.0 | 39 |
| 168 | Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitorâ€”Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. <i>Oncologist</i> , 2008, 13, 503-514. | 1.9 | 165 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 169 | Disorders of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent. , 2008, , 686-769. | | 15 |
| 170 | Alendronate for the treatment of osteoporosis in men. Expert Opinion on Pharmacotherapy, 2008, 9, 491-498. | 0.9 | 8 |
| 171 | ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. American Journal of Health-System Pharmacy, 2008, 65, 343-357. | 0.5 | 12 |
| 172 | Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. Climacteric, 2008, 11, 287-295. | 1.1 | 13 |
| 173 | Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy—a case report. Monthly Notices of the Royal Astronomical Society: Letters, 2008, 79, 565-567. | 1.2 | 53 |
| 174 | Severely Suppressed Bone Turnover and Atypical Skeletal Fragility. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2948-2952. | 1.8 | 247 |
| 175 | More on Atypical Fractures of the Femoral Diaphysis. New England Journal of Medicine, 2008, 359, 316-318. | 13.9 | 43 |
| 176 | Drug Insight: choosing a drug treatment strategy for women with osteoporosis—an evidence-based clinical perspective. Nature Clinical Practice Rheumatology, 2008, 4, 240-248. | 3.2 | 29 |
| 177 | Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis. Yearbook of Endocrinology, 2008, 2008, 219-221. | 0.0 | 0 |
| 178 | Effects of Continuing or Stopping Alendronate After 5 Years of Treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A Randomized Trial. Yearbook of Endocrinology, 2008, 2008, 217-219. | 0.0 | 0 |
| 179 | Miscellaneous drugs, materials, medical devices, and techniques. Side Effects of Drugs Annual, 2008, 30, 561-575. | 0.6 | 0 |
| 180 | Subtrochanteric Femoral Insufficiency Fracture Following Bisphosphonate Therapy for Osseous Metastases. Radiology Case Reports, 2008, 3, 232. | 0.2 | 19 |
| 181 | New developments surrounding the safety of bisphosphonates. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 508-513. | 1.2 | 8 |
| 182 | Low-Energy Femoral Shaft Fractures Associated With Alendronate Use. Journal of Orthopaedic Trauma, 2008, 22, 346-350. | 0.7 | 467 |
| 183 | Osteoporosis: how long should we treat?. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 502-507. | 1.2 | 19 |
| 184 | Bisphosphonate-Associated Osteomyelitis of the Jaw: Guidelines for Practicing Clinicians. Endocrine Practice, 2008, 14, 1150-1168. | 1.1 | 13 |
| 185 | Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture. Southern Medical Journal, 2009, 102, 397-404. | 0.3 | 11 |
| 186 | Current options for the treatment of Paget's disease of the bone. Open Access Rheumatology: Research and Reviews, 2009, 1, 107. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 187 | Bone Modeling and Remodeling. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2009, 19, 219-233. | 0.4 | 166 |
| 188 | Musculoskeletal Injuries in the Elderly. , 0, , 324-335. | | 0 |
| 189 | Once-monthly risedronate for postmenopausal osteoporosis. <i>International Journal of Women's Health</i> , 2009, 1, 1. | 1.1 | 1 |
| 190 | Pharmacotherapy of Paget's Disease of Bone: Focus on Zoledronic Acid. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1095. | 0.1 | 0 |
| 191 | Pharmacotherapy Options in Cancer Treatment-induced Bone Loss: Focus on Bisphosphonates. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2064. | 0.1 | 0 |
| 192 | Bisphosphonate-associated adverse events. <i>Hormones</i> , 2009, 8, 96-110. | 0.9 | 231 |
| 193 | Identification and Treatment of Osteoporosis among Elderly Patients with Hip Fractures. <i>Clinics</i> , 2009, 64, 1201-1204. | 0.6 | 12 |
| 194 | Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates. <i>Endocrine Practice</i> , 2009, 15, 483-493. | 1.1 | 23 |
| 195 | Long-Term Alendronate Use Not without Consequences?. <i>International Journal of Rheumatology</i> , 2009, 2009, 1-6. | 0.9 | 13 |
| 196 | The Cost-Effectiveness of an RCT to Establish Whether 5 or 10 Years of Bisphosphonate Treatment Is the Better Duration for Women With a Prior Fracture. <i>Medical Decision Making</i> , 2009, 29, 678-689. | 1.2 | 19 |
| 197 | Paget's disease of bone: a review of epidemiology, pathophysiology and management. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009, 1, 107-125. | 1.2 | 64 |
| 198 | Bisphosphonates and Osteonecrosis of the Jaw: Moving from the Bedside to the Bench. <i>Cells Tissues Organs</i> , 2009, 189, 289-294. | 1.3 | 56 |
| 199 | Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. <i>Mayo Clinic Proceedings</i> , 2009, 84, 632-638. | 1.4 | 340 |
| 200 | The Use of Intravenous Aminobisphosphonates for the Treatment of Paget's Disease of Bone. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1052-1063. | 1.1 | 20 |
| 201 | Transplantation of Mesenchymal Stem Cells Overexpressing RANK-Fc or CXCR4 Prevents Bone Loss in Ovariectomized Mice. <i>Molecular Therapy</i> , 2009, 17, 1979-1987. | 3.7 | 76 |
| 202 | Bisphosphonates and fatigue fractures. <i>IBMS BoneKEy</i> , 2009, 6, 465-469. | 0.1 | 6 |
| 203 | Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis. <i>Hormone and Metabolic Research</i> , 2009, 41, 721-729. | 0.7 | 91 |
| 204 | Recent advances in the management of osteoporosis. <i>Clinical Medicine</i> , 2009, 9, 565-569. | 0.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 205 | Postoperative management of hip fractures. <i>IBMS BoneKEy</i> , 2009, 6, 55-62. | 0.1 | 0 |
| 206 | Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy. <i>Journal of Bone and Joint Surgery - Series A</i> , 2009, 91, 2556-2561. | 1.4 | 206 |
| 207 | High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties. <i>Clinical Cancer Research</i> , 2009, 15, 5829-5839. | 3.2 | 90 |
| 208 | Spontaneous femoral shaft fracture after long-term alendronate. <i>Age and Ageing</i> , 2009, 38, 625-626. | 0.7 | 29 |
| 209 | Denosumab in postmenopausal osteoporosis: what the clinician needs to know. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009, 1, 13-26. | 1.2 | 13 |
| 210 | Recurrent Low-Energy Femoral Shaft Fractures and Osteonecrosis of the Jaw in a Case of Multiple Myeloma Treated With Bisphosphonates. <i>Journal of Oral and Maxillofacial Surgery</i> , 2009, 67, 645-649. | 0.5 | 22 |
| 211 | Reconstruction of Defects Caused by Bisphosphonate-Induced Osteonecrosis of the Jaws. <i>Journal of Oral and Maxillofacial Surgery</i> , 2009, 67, 107-119. | 0.5 | 86 |
| 212 | Strategies for treatment to prevent fragility fractures in postmenopausal women. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 727-740. | 1.4 | 11 |
| 213 | Bone health and osteoporosis in postmenopausal women. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2009, 23, 73-85. | 1.4 | 36 |
| 214 | Response to "Fatigue having a role in pathogenesis of osteonecrosis of the jaws" and "BRONJ and the microdamage Letter to the Editor". <i>Clinical Oral Investigations</i> , 2009, 13, 483-484. | 1.4 | 1 |
| 215 | Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy. <i>Clinical Orthopaedics and Related Research</i> , 2009, 467, 1921-1926. | 0.7 | 83 |
| 216 | Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment. <i>Current Osteoporosis Reports</i> , 2009, 7, 12-17. | 1.5 | 26 |
| 217 | Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series. <i>Calcified Tissue International</i> , 2009, 85, 37-44. | 1.5 | 105 |
| 218 | Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys. <i>Calcified Tissue International</i> , 2009, 85, 344-355. | 1.5 | 44 |
| 219 | Use of bisphosphonates for the treatment of stress fractures in athletes. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2009, 17, 542-550. | 2.3 | 31 |
| 220 | Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. <i>Osteoporosis International</i> , 2009, 20, 647-652. | 1.3 | 14 |
| 221 | Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. <i>Osteoporosis International</i> , 2009, 20, 1353-1362. | 1.3 | 341 |
| 222 | To stop or not to stop, that is the question. <i>Osteoporosis International</i> , 2009, 20, 187-195. | 1.3 | 47 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 223 | Bone microdamage: a clinical perspective. <i>Osteoporosis International</i> , 2009, 20, 1299-1308. | 1.3 | 77 |
| 224 | Thinking inside and outside the envelopes of bone. <i>Osteoporosis International</i> , 2009, 20, 1281-1288. | 1.3 | 49 |
| 225 | Bone protective therapy in the young patient with fractures and chronic disease: what drug(s) should be given and for how long?. <i>Clinical Endocrinology</i> , 2009, 70, 188-191. | 1.2 | 3 |
| 226 | Clinical applications of RANK ligand inhibition. <i>Internal Medicine Journal</i> , 2009, 39, 110-116. | 0.5 | 23 |
| 227 | Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2009, 135, 361-374. | 0.8 | 54 |
| 228 | Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1095-1102. | 3.1 | 316 |
| 229 | Atypical Femoral Fractures, Bisphosphonates, and Adult Hypophosphatasia. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1132-1134. | 3.1 | 124 |
| 231 | Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1544-1551. | 3.1 | 108 |
| 232 | Bilateral Fractures of the Femur Diaphysis in a Patient With Rheumatoid Arthritis on Long-Term Treatment With Alendronate: Clues to the Mechanism of Increased Bone Fragility. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1736-1740. | 3.1 | 123 |
| 233 | Lithium's effect on bone mineral density. <i>Bone</i> , 2009, 44, 331-334. | 1.4 | 183 |
| 234 | Optimal increase in bone mass by continuous local infusion of alendronate during distraction osteogenesis in rabbits. <i>Bone</i> , 2009, 44, 917-923. | 1.4 | 24 |
| 235 | Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. <i>Bone</i> , 2009, 44, 766-771. | 1.4 | 7 |
| 237 | Comparison of Radiographic Fracture Healing in the Distal Radius for Patients on and off Bisphosphonate Therapy. <i>Journal of Hand Surgery</i> , 2009, 34, 595-602. | 0.7 | 87 |
| 238 | Vascular calcification and bone disease: the calcification paradox. <i>Trends in Molecular Medicine</i> , 2009, 15, 405-416. | 3.5 | 255 |
| 239 | Safety of Bisphosphonates in the Treatment of Osteoporosis. <i>American Journal of Medicine</i> , 2009, 122, S22-S32. | 0.6 | 84 |
| 240 | Assessing Fracture Risk and Effects of Osteoporosis Drugs: Bone Mineral Density and Beyond. <i>American Journal of Medicine</i> , 2009, 122, 992-997. | 0.6 | 20 |
| 241 | Potential new drug targets for osteoporosis. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 20-27. | 3.2 | 141 |
| 242 | Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates. <i>Drug Safety</i> , 2009, 32, 775-785. | 1.4 | 118 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 243 | Clodronic Acid Formulations Available in Europe and their Use in Osteoporosis. <i>Clinical Drug Investigation</i> , 2009, 29, 359-379. | 1.1 | 15 |
| 244 | Bisphosphonate-Related Osteonecrosis of the Jaw: Diagnosis, Prevention, and Management. <i>Annual Review of Medicine</i> , 2009, 60, 85-96. | 5.0 | 83 |
| 245 | Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy. <i>New England Journal of Medicine</i> , 2009, 360, 53-62. | 13.9 | 332 |
| 246 | RANKL inhibition for the management of patients with benign metabolic bone disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1085-1102. | 1.9 | 30 |
| 247 | Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. <i>International Journal of Rheumatic Diseases</i> , 2009, 12, 149-154. | 0.9 | 27 |
| 248 | Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. <i>Mayo Clinic Proceedings</i> , 2009, 84, 632-638. | 1.4 | 281 |
| 249 | Bisphosphonates and metabolic bone disease in the ICU. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2009, 12, 190-195. | 1.3 | 16 |
| 250 | Pharmacotherapeutic management of osteoporosis and osteopenia. <i>Nurse Practitioner</i> , 2009, 34, 30-40. | 0.2 | 9 |
| 251 | CTX Biochemical Marker of Bone Metabolism. Is it a Reliable Predictor of Bisphosphonate-Associated Osteonecrosis of the Jaws After Surgery? Part I: Biological Concepts With a Review of the Literature. <i>Implant Dentistry</i> , 2009, 18, 492-500. | 1.7 | 22 |
| 252 | Subtrochanteric Femoral Insufficiency Fracture in Woman on Bisphosphonate Therapy for Glucocorticoid-Induced Osteoporosis. <i>Radiology Case Reports</i> , 2009, 4, 261. | 0.2 | 11 |
| 253 | Bisphosphonate Use in Acute and Chronic Spinal Cord Injury: A Systematic Review. <i>Journal of Spinal Cord Medicine</i> , 2009, 32, 215-225. | 0.7 | 44 |
| 254 | éãâãžæš'â'ªâ%œéã²—â-â,†â‡ç—‡. <i>Kagaku To Seibutsu</i> , 2009, 47, 51-58. | 0.0 | 0 |
| 255 | Future therapeutic targets in osteoporosis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 380-385. | 2.0 | 65 |
| 256 | Femoral Cortical Stress Lesions in Long-Term Bisphosphonate Therapy: A Herald of Impending Fracture?. <i>Journal of Orthopaedic Trauma</i> , 2010, 24, 75-81. | 0.7 | 129 |
| 257 | Effects of Yearly Zoledronic Acid 5mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis. <i>Yearbook of Endocrinology</i> , 2010, 2010, 214-216. | 0.0 | 0 |
| 258 | Management of osteoporosis in postmenopausal women. <i>Menopause</i> , 2010, 17, 25-54. | 0.8 | 369 |
| 259 | Newer Therapies for Osteoporosis. <i>American Journal of Therapeutics</i> , 2010, 17, 197-200. | 0.5 | 4 |
| 260 | Care Required When Using Bisphosphonates in Dental Surgical Practice. <i>Journal of Craniofacial Surgery</i> , 2010, 21, 1966-1970. | 0.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 261 | Atypical Insufficiency Fracture of the Tibia Associated With Long-Term Bisphosphonate Therapy. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 76-78. | 0.5 | 40 |
| 262 | Osteoporosis Treatment Following Hip Fracture: How Rates Vary by Service. <i>Southern Medical Journal</i> , 2010, 103, 977-981. | 0.3 | 13 |
| 263 | Screening for Osteoporosis: An Update for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2010, 153, 99. | 2.0 | 172 |
| 264 | Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). <i>Journal of Bone and Mineral Research</i> , 2010, 25, 48-55. | 3.1 | 82 |
| 265 | Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 98-105. | 3.1 | 72 |
| 266 | Adverse Effects of Bisphosphonates. <i>Calcified Tissue International</i> , 2010, 86, 421-435. | 1.5 | 139 |
| 267 | Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone,) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 International, 2010, 87, 469-484. | 1.5 | 82 |
| 268 | Fragility fractures of the hip and femur: incidence and patient characteristics. <i>Osteoporosis International</i> , 2010, 21, 399-408. | 1.3 | 239 |
| 269 | Alendronate-related femoral diaphysis fractureâ€”what should be done to predict and prevent subsequent fracture of the contralateral side?. <i>Osteoporosis International</i> , 2010, 21, 701-703. | 1.3 | 46 |
| 270 | Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. <i>Osteoporosis International</i> , 2010, 21, 705-708. | 1.3 | 24 |
| 271 | Effects of combination treatment with alendronate and vitamin K2 on bone mineral density and strength in ovariectomized mice. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 403-409. | 1.3 | 26 |
| 272 | Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 713-718. | 1.3 | 12 |
| 273 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. <i>Clinical Oral Investigations</i> , 2010, 14, 271-284. | 1.4 | 95 |
| 275 | Subtrochanteric femoral insufficiency fractures related to the use of long-term bisphosphonates: a pictorial review. <i>Emergency Radiology</i> , 2010, 17, 511-515. | 1.0 | 14 |
| 276 | Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy. <i>Clinical Orthopaedics and Related Research</i> , 2010, 468, 1991-1996. | 0.7 | 56 |
| 277 | Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy. <i>Clinical Orthopaedics and Related Research</i> , 2010, 468, 3384-3392. | 0.7 | 84 |
| 278 | Is Surgery Necessary for Femoral Insufficiency Fractures after Long-term Bisphosphonate Therapy?. <i>Clinical Orthopaedics and Related Research</i> , 2010, 468, 3393-3398. | 0.7 | 109 |
| 279 | Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia. <i>Journal of Children's Orthopaedics</i> , 2010, 4, 507-517. | 0.4 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 280 | Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates. <i>Current Osteoporosis Reports</i> , 2010, 8, 34-39. | 1.5 | 77 |
| 281 | Diagnosis and Management of Mineral Metabolism in CKD. <i>Journal of General Internal Medicine</i> , 2010, 25, 710-716. | 1.3 | 14 |
| 282 | Stabilized severe osteoporosis: should the treatment be stopped?. <i>Joint Bone Spine</i> , 2010, 77, S120-S127. | 0.8 | 4 |
| 283 | Prosthetic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: A clinical report. <i>Journal of Prosthetic Dentistry</i> , 2010, 103, 196-201. | 1.1 | 25 |
| 284 | Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schönberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2515-2526. | 3.1 | 38 |
| 285 | Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2267-2294. | 3.1 | 994 |
| 286 | The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regeneration. <i>Biomaterials</i> , 2010, 31, 8674-8683. | 5.7 | 115 |
| 287 | Faut-il interrompre le traitement d'une ostéoporose sévère qui est stabilisée ?. <i>Revue Du Rhumatisme (Edition Française)</i> , 2010, 77, S60-S67. | 0.0 | 0 |
| 288 | Unusual midshaft fractures during long-term bisphosphonate therapy. <i>Clinical Endocrinology</i> , 2010, 72, 161-168. | 1.2 | 154 |
| 289 | Atypical femur fractures: a complication of prolonged bisphosphonate therapy?. <i>Medical Journal of Australia</i> , 2010, 193, 196-198. | 0.8 | 8 |
| 290 | Bisphosphonates in the treatment of metabolic bone diseases. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 206-212. | 1.3 | 16 |
| 291 | Bisphosphonate-induced femoral fragility fractures: What do we know?. <i>Orthopedic Research and Reviews</i> , 0, Volume 2, 27-34. | 0.7 | 2 |
| 292 | Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. <i>Drug Design, Development and Therapy</i> , 2010, 4, 321. | 2.0 | 22 |
| 293 | Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 121. | 1.0 | 42 |
| 294 | Glucocorticoid-induced osteoporosis: how best to avoid fractures. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 17-23. | 1.1 | 2 |
| 295 | Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 559-566. | 1.8 | 47 |
| 296 | Bisphosphonates for the treatment of osteoporosis: insights for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 115-128. | 1.1 | 84 |
| 297 | Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1480. | 3.8 | 99 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 298 | Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. <i>New England Journal of Medicine</i> , 2010, 362, 1761-1771. | 13.9 | 456 |
| 299 | Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers. <i>Clinical Infectious Diseases</i> , 2010, 51, 937-946. | 2.9 | 338 |
| 300 | Central dislocation of the hip secondary to insufficiency fracture. <i>Orthopedic Reviews</i> , 2010, 2, 5. | 0.3 | 0 |
| 301 | Risks and benefits of long-term bisphosphonate therapy. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 994-1001. | 0.5 | 24 |
| 302 | NOFSA Guideline for the Diagnosis and Management of Osteoporosis. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2010, 15, 107-108. | 0.4 | 16 |
| 303 | Evolving Data about Subtrochanteric Fractures and Bisphosphonates. <i>New England Journal of Medicine</i> , 2010, 362, 1825-1827. | 13.9 | 74 |
| 304 | Bisphosphonate Use in Chronic Kidney Disease: Association with Adynamic Bone Disease in a Bone Histology Series. <i>Blood Purification</i> , 2010, 29, 293-299. | 0.9 | 56 |
| 305 | Bisphosphonate Use and Atypical Femoral Fractures: Getting Down to Brass Tacks. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5207-5209. | 1.8 | 2 |
| 306 | Subtrochanteric Femoral Fractures in Patients Receiving Long-Term Alendronate Therapy: Imaging Features. <i>American Journal of Roentgenology</i> , 2010, 194, 1581-1586. | 1.0 | 55 |
| 307 | Low-Energy Femoral Fractures Associated With Long-Term Bisphosphonate Use in a Rehabilitation Setting: A Case Series. <i>PM and R</i> , 2010, 2, 76-80. | 0.9 | 16 |
| 308 | A rational approach to management of alendronate-related subtrochanteric fractures. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2010, 92-B, 679-686. | 3.4 | 105 |
| 309 | Bisphosphonates and atypical femoral fractures: A time for reflection. <i>Maturitas</i> , 2010, 65, 3-4. | 1.0 | 16 |
| 310 | Should bisphosphonates be used in premenopausal women?. <i>Maturitas</i> , 2010, 66, 3-4. | 1.0 | 9 |
| 311 | Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. <i>Bone</i> , 2010, 46, 1038-1042. | 1.4 | 62 |
| 312 | Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. <i>Bone</i> , 2010, 47, 480-492. | 1.4 | 69 |
| 313 | Atypical fractures of the femur and bisphosphonate therapy. <i>Bone</i> , 2010, 47, 169-180. | 1.4 | 248 |
| 314 | Reference intervals of biochemical bone turnover markers for Saudi Arabian women: A cross-sectional study. <i>Bone</i> , 2010, 47, 804-814. | 1.4 | 60 |
| 316 | Research on relationship between FPN1 content and effect of hepcidin on intracellular calcium and iron ions change in osteoblasts. <i>Bone</i> , 2010, 47, S406. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 317 | Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. <i>European Journal of Cancer</i> , 2010, 46, 558-565. | 1.3 | 37 |
| 318 | Non-Surgical Chemotherapeutic Treatment Strategies for the Management of Periodontal Diseases. <i>Dental Clinics of North America</i> , 2010, 54, 13-33. | 0.8 | 68 |
| 319 | Tratamiento de la osteoporosis con bifosfonatos. Diferencias por mecanismo de acción. Datos de eficacia y seguridad a largo plazo. <i>Medicine</i> , 2010, 10, 4135-4143. | 0.0 | 0 |
| 320 | Long-Term Use of Bisphosphonates in Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1555-1565. | 1.8 | 447 |
| 321 | Bisphosphonates for Osteoporosis. <i>New England Journal of Medicine</i> , 2010, 363, 2027-2035. | 13.9 | 184 |
| 322 | Five-year follow-up of Japanese patients with Paget's disease of the bone after treatment with low-dose oral alendronate: a case series. <i>Journal of Medical Case Reports</i> , 2010, 4, 166. | 0.4 | 6 |
| 323 | The pathogenesis, diagnosis, investigation and management of osteoporosis. <i>Journal of Clinical Pathology</i> , 2011, 64, 1042-1050. | 1.0 | 110 |
| 324 | Zoledronic acid for prevention and treatment of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 807-815. | 0.9 | 19 |
| 325 | Small Interfering RNA Knocks Down the Molecular Target of Alendronate, Farnesyl Pyrophosphate Synthase, in Osteoclast and Osteoblast Cultures. <i>Molecular Pharmaceutics</i> , 2011, 8, 1016-1024. | 2.3 | 15 |
| 326 | Long-term Safety Concerns of Antiresorptive Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2011, 37, 387-400. | 0.8 | 17 |
| 327 | Osteoporosis Update From the 2010 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2011, 14, 1-21. | 0.5 | 22 |
| 328 | Adverse effects of bisphosphonates. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 189-197. | 0.2 | 1 |
| 329 | Evaluation of Bone Fragility and Fracture Prevention. , 2011, , 309-328. | | 2 |
| 331 | Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis. <i>Drugs</i> , 2011, 71, 791-814. | 4.9 | 75 |
| 332 | Fractures in the Elderly. , 2011, , . | | 1 |
| 333 | The role and efficacy of denosumab in the treatment of osteoporosis: an update. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 205-217. | 1.0 | 21 |
| 334 | Bisphosphonate-Related Subtrochanteric Femoral Fractures. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 194-198. | 3.0 | 10 |
| 335 | The societal burden of poor persistence to treatment of osteoporosis in Sweden. <i>Bone</i> , 2011, 48, 380-388. | 1.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 336 | Denosumab and bisphosphonates: Different mechanisms of action and effects. <i>Bone</i> , 2011, 48, 677-692. | 1.4 | 556 |
| 337 | Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. <i>Bone</i> , 2011, 48, 966-971. | 1.4 | 164 |
| 338 | Safety of bisphosphonates. <i>Bone</i> , 2011, 49, 103-110. | 1.4 | 135 |
| 339 | Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures. <i>Bone</i> , 2011, 48, 963-965. | 1.4 | 10 |
| 340 | Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. <i>Bone</i> , 2011, 49, 151-161. | 1.4 | 92 |
| 341 | Bisphosphonates: The first 40years. <i>Bone</i> , 2011, 49, 2-19. | 1.4 | 929 |
| 342 | Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. <i>Bone</i> , 2011, 49, 1279-1289. | 1.4 | 61 |
| 343 | Bone freezing and bisphosphonates. <i>Maturitas</i> , 2011, 69, 1-2. | 1.0 | 1 |
| 344 | Panax notoginseng saponins promotes proliferation and osteogenic differentiation of rat bone marrow stromal cells. <i>Journal of Ethnopharmacology</i> , 2011, 134, 268-274. | 2.0 | 39 |
| 347 | Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1303-1312. | 3.1 | 113 |
| 349 | Atypical fractures associated with the long term use of bisphosphonates. The current situation. <i>Revista Española De Cirugía Ortopédica Y Traumatología</i> , 2011, 55, 392-404. | 0.1 | 3 |
| 350 | Tratamiento de la osteopenia y la osteoporosis. <i>Medicine</i> , 2011, 10, 6221-6229. | 0.0 | 1 |
| 351 | Bisphosphonates and Atypical Fractures of Femur. <i>Journal of Osteoporosis</i> , 2011, 2011, 1-5. | 0.1 | 3 |
| 352 | The Effects of Combination Therapy of Cathepsin K Inhibitor and PTH on Change in Bone Mineral Density in an Animal Model of Osteoporosis. <i>Endocrinology and Metabolism</i> , 2011, 26, 303. | 1.3 | 1 |
| 353 | Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 157. | 0.9 | 32 |
| 354 | The effects of discontinuing long term alendronate therapy in a clinical practice setting. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2011, 55, 272-278. | 1.3 | 5 |
| 356 | Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. <i>Drug, Healthcare and Patient Safety</i> , 2011, 3, 79. | 1.0 | 31 |
| 357 | Medicamentos para o tratamento da osteoporose: revisão. <i>Revista Brasileira De Reumatologia</i> , 2011, 51, 372-382. | 0.8 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 359 | Alendronate-Associated Ulnar and Tibial Fractures: A Case Report. <i>Journal of Orthopaedic Surgery</i> , 2011, 19, 370-372. | 0.4 | 18 |
| 360 | Update on Hormone Replacement Therapy. <i>Postgraduate Obstetrics & Gynecology</i> , 2011, 31, 1-7. | 0.1 | 0 |
| 361 | Atypical Bilateral Pedicle Fracture in Long-Term Bisphosphonate Therapy. <i>Spine</i> , 2011, 36, E1769-E1773. | 1.0 | 14 |
| 362 | The Outcome of Surgically Treated Femur Fractures Associated With Long-Term Bisphosphonate Use. <i>Journal of Trauma</i> , 2011, 71, 186-190. | 2.3 | 136 |
| 363 | Update on Hormone Replacement Therapy. <i>Postgraduate Obstetrics & Gynecology</i> , 2011, 31, 8. | 0.1 | 0 |
| 365 | Alendronate-Associated Femoral Insufficiency Fractures and Femoral Stress Reactions. <i>Journal of Orthopaedic Surgery</i> , 2011, 19, 89-92. | 0.4 | 29 |
| 366 | Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. <i>Journal of Periodontal Research</i> , 2011, 46, 39-47. | 1.4 | 39 |
| 367 | Bisphosphonate-related osteonecrosis of the jaw: an overview. <i>Annals of the New York Academy of Sciences</i> , 2011, 1218, 38-46. | 1.8 | 98 |
| 368 | Clinical Utility of Serum Bone Turnover Markers in Postmenopausal Osteoporosis Therapy Monitoring: A Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 157-169. | 1.6 | 28 |
| 369 | Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 178-186. | 1.6 | 43 |
| 370 | Bilateral stress fracture of the femoral shaft after total knee arthroplasty. <i>Knee</i> , 2011, 18, 354-357. | 0.8 | 12 |
| 371 | Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series. <i>Journal of Medical Case Reports</i> , 2011, 5, 349. | 0.4 | 8 |
| 372 | Femoral shaft fractures in the elderly – Role of prior bisphosphonate therapy. <i>Injury</i> , 2011, 42, 702-706. | 0.7 | 9 |
| 373 | What do we know about atypical femoral fractures? Insights and enigmas. <i>Joint Bone Spine</i> , 2011, 78, 568-571. | 0.8 | 11 |
| 374 | Hip and Subtrochanteric or Diaphyseal Femoral Fractures in Alendronate Users: A 10-Year, Nationwide Retrospective Cohort Study in Taiwanese Women. <i>Clinical Therapeutics</i> , 2011, 33, 1659-1667. | 1.1 | 36 |
| 375 | Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2011, 139, e267-e277. | 0.8 | 17 |
| 376 | Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). <i>Breast Cancer Research and Treatment</i> , 2011, 125, 99-106. | 1.1 | 31 |
| 377 | Course of NTX changes under continuous bisphosphonate treatment in cases of NTX over-reduction due to long-term treatment with bisphosphonates. <i>Journal of Orthopaedic Science</i> , 2011, 16, 71-76. | 0.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 378 | Simultaneous bilateral subtrochanteric fractures following risedronate therapy. <i>Journal of Orthopaedic Science</i> , 2011, 16, 467-470. | 0.5 | 8 |
| 379 | Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy. <i>Rheumatology International</i> , 2011, 31, 973-975. | 1.5 | 8 |
| 381 | Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. <i>Osteoporosis International</i> , 2011, 22, 373-390. | 1.3 | 220 |
| 382 | Association between timing of zoledronic acid infusion and hip fracture healing. <i>Osteoporosis International</i> , 2011, 22, 2329-2336. | 1.3 | 89 |
| 383 | Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. <i>Osteoporosis International</i> , 2011, 22, 2951-2961. | 1.3 | 102 |
| 384 | Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. <i>Calcified Tissue International</i> , 2011, 89, 91-104. | 1.5 | 170 |
| 385 | Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial. <i>Calcified Tissue International</i> , 2011, 89, 427-433. | 1.5 | 12 |
| 386 | Diseases Affecting Bone Quality: Beyond Osteoporosis. <i>Clinical Orthopaedics and Related Research</i> , 2011, 469, 2194-2206. | 0.7 | 65 |
| 387 | Nonoperative versus Prophylactic Treatment of Bisphosphonate-associated Femoral Stress Fractures. <i>Clinical Orthopaedics and Related Research</i> , 2011, 469, 2028-2034. | 0.7 | 116 |
| 388 | The Effect of Antiresorptives on Bone Quality. <i>Clinical Orthopaedics and Related Research</i> , 2011, 469, 2207-2214. | 0.7 | 21 |
| 389 | An innovative herbal product for the prevention of osteoporosis. <i>Chinese Journal of Integrative Medicine</i> , 2011, 17, 744-749. | 0.7 | 12 |
| 390 | Osteoporosis: burden, health care provision and opportunities in the EU. <i>Archives of Osteoporosis</i> , 2011, 6, 59-155. | 1.0 | 459 |
| 391 | Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996-2007. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 553-560. | 3.1 | 136 |
| 392 | The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: Results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 538-545. | 3.1 | 31 |
| 393 | Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 993-1001. | 3.1 | 79 |
| 394 | Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?. <i>Arthritis and Rheumatism</i> , 2011, 63, 325-328. | 6.7 | 47 |
| 395 | Metabolic bone disease: Atypical femoral fractures. <i>Journal of Biomechanics</i> , 2011, 44, 244-247. | 0.9 | 7 |
| 396 | Fracture risk associated with chronic use of bisphosphonates: evidence today. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 67-76. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 397 | Atypical Femoral Fractures during Prolonged Use of Bisphosphonates: Short-Term Responses to Strontium Ranelate and Teriparatide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2675-2680. | 1.8 | 80 |
| 398 | Bisphosphonate-Related Complete Atypical Subtrochanteric Femoral Fractures: Diagnostic Utility of Radiography. <i>American Journal of Roentgenology</i> , 2011, 197, 954-960. | 1.0 | 53 |
| 399 | Subtrochanteric Insufficiency Fractures Associated With Bisphosphonate Use: 2 Case Reports and Review. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2011, 2, 105-109. | 0.6 | 0 |
| 400 | Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 657-674. | 0.9 | 23 |
| 401 | Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. <i>European Journal of Endocrinology</i> , 2011, 165, 647-655. | 1.9 | 47 |
| 402 | Safety of drugs used in the treatment of osteoporosis. <i>Therapeutic Advances in Drug Safety</i> , 2011, 2, 159-172. | 1.0 | 28 |
| 403 | Long-term bisphosphonate usage and subtrochanteric insufficiency fractures. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2011, 93-B, 1289-1295. | 3.4 | 45 |
| 404 | Pubic rami and sacral insufficiency fractures resulting in osteomyelitis, vulval abscess, discharging bone fragments and pelvic instability. <i>JRSM Short Reports</i> , 2011, 2, 1-5. | 0.6 | 2 |
| 405 | <i>Panax Notoginseng</i> Saponins Promote Osteogenic Differentiation of Bone Marrow Stromal Cells Through the ERK and P38 MAPK Signaling Pathways. <i>Cellular Physiology and Biochemistry</i> , 2011, 28, 367-376. | 1.1 | 34 |
| 406 | Atypical femur fractures: a review of the evidence and its implication to clinical practice. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011, 3, 301-314. | 1.2 | 33 |
| 407 | Atypical Subtrochanteric Femoral Fractures in Patients with Skeletal Malignant Involvement Treated with Intravenous Bisphosphonates. <i>Journal of Bone and Joint Surgery - Series A</i> , 2011, 93, 1235-1242. | 1.4 | 92 |
| 408 | Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. <i>Journal of the American Dental Association</i> , 2011, 142, 1243-1251. | 0.7 | 317 |
| 409 | Osteoporosis following organ transplantation: pathogenesis, diagnosis and management. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 157-176. | 1.2 | 2 |
| 410 | Bisphosphonate Use and Atypical Fractures of the Femoral Shaft. <i>New England Journal of Medicine</i> , 2011, 364, 1728-1737. | 13.9 | 649 |
| 411 | Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2011, 93-B, 1134-1139. | 3.4 | 34 |
| 412 | Metatarsal Stress Fractures in Patients with Multiple Myeloma Treated with Long-Term Bisphosphonates. <i>Journal of Bone and Joint Surgery - Series A</i> , 2011, 93, e106. | 1.4 | 12 |
| 413 | Bisphosphonates for post-menopausal osteoporosis: are they all the same?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 281-300. | 0.2 | 50 |
| 414 | The Role of Vitamin D in Orthopedic Surgery. , 2011, , 927-944. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 415 | Atypical metatarsal fracture in a patient on long term bisphosphonate therapy. Indian Journal of Orthopaedics, 2012, 46, 589-592. | 0.5 | 6 |
| 416 | Atypical femoral fractures and bisphosphonate treatment. Journal of Bone and Joint Surgery: British Volume, 2012, 94-B, 385-390. | 3.4 | 103 |
| 417 | Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing. Journal of Bone and Joint Surgery - Series A, 2012, 94, 2113-2119. | 1.4 | 107 |
| 418 | Atypical femoral fractures related to bisphosphonate therapy. Indian Journal of Radiology and Imaging, 2012, 22, 178-181. | 0.3 | 8 |
| 419 | Atypical femoral fractures. Current Opinion in Supportive and Palliative Care, 2012, 6, 348-354. | 0.5 | 42 |
| 420 | Atypical Femoral Fracture Risk in Patients Treated With Bisphosphonates. Archives of Internal Medicine, 2012, 172, 936-7. | 4.3 | 6 |
| 421 | Atypical Subtrochanteric Femoral Fracture. Journal of Orthopaedic and Sports Physical Therapy, 2012, 42, 44-44. | 1.7 | 4 |
| 422 | Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels. Current Medical Research and Opinion, 2012, 28, 1547-1552. | 0.9 | 11 |
| 423 | Bisphosphonate-Related Femoral Periosteal Stress Reactions: Scoring System Based on Radiographic and MRI Findings. American Journal of Roentgenology, 2012, 198, 869-877. | 1.0 | 30 |
| 424 | Atypical Femur Fractures: 81 Individual Personal Histories. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4324-4328. | 1.8 | 32 |
| 425 | Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and Pharmacokinetics of the Cathepsin K Inhibitor, ONO-5334, in an Ascending Multiple-Dose, Phase 1 Study. Journal of Clinical Pharmacology, 2012, 52, 306-318. | 1.0 | 24 |
| 426 | Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1440-E1449. | 1.8 | 35 |
| 427 | A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture. Journal of Bone and Joint Surgery: British Volume, 2012, 94-B, 994-997. | 3.4 | 46 |
| 428 | Bilateral Femoral Diaphyseal Fractures After Long-Term Bisphosphonates Therapy: A Case Report. Turk Osteoporoz Dergisi, 2012, 18, 92-94. | 0.0 | 2 |
| 429 | Periprosthetic Femoral Insufficiency Fracture in a Patient on Long-term Bisphosphonate Therapy. The Duke Orthopaedic Journal, 2012, 2, 66-69. | 0.0 | 12 |
| 430 | Are Women with Thicker Cortices in the Femoral Shaft at Higher Risk of Subtrochanteric/Diaphyseal Fractures? The Study of Osteoporotic Fractures. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2414-2422. | 1.8 | 23 |
| 431 | Importance of reversible remodeling suppression with denosumab. IBMS BoneKEy, 2012, 9, . | 0.1 | 0 |
| 432 | Possible Role of Oral Ibandronate Administration in Osteonecrosis of the Jaw: A Case Report. International Journal of Immunopathology and Pharmacology, 2012, 25, 311-316. | 1.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 433 | Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman. <i>Menopause</i> , 2012, 19, 1360-1363. | 0.8 | 40 |
| 434 | Femoral Canal Obliteration Secondary to Prolonged Alendronate Use: A Case Report. <i>Journal of Orthopaedic Surgery</i> , 2012, 20, 115-117. | 0.4 | 10 |
| 435 | Treatment of Femoral Fracture Nonunion After Long-term Bisphosphonate Use. <i>Orthopedics</i> , 2012, 35, e991-5. | 0.5 | 38 |
| 436 | Sequential bilateral femoral fractures. <i>BMJ, The</i> , 2012, 345, e7361-e7361. | 3.0 | 1 |
| 437 | Atypical Bilateral Fracture of the Femoral Diaphysis in Bisphosphonate Therapy. <i>Orthopedics & Traumatology</i> , 2012, 61, 280-282. | 0.0 | 0 |
| 438 | Atypical Femoral Fracture during Long-term Bisphosphonate Therapy: A Case Report. <i>Orthopedics & Traumatology</i> , 2012, 61, 795-798. | 0.0 | 0 |
| 439 | Clinical Study of the Relationship between Femoral Shaft Fracture Type and Usage of Bisphosphonates. <i>Orthopedics & Traumatology</i> , 2012, 61, 799-802. | 0.0 | 0 |
| 440 | Early Initiation of Bisphosphonate does not Affect Healing and Outcomes of Volar Plate Fixation of Osteoporotic Distal Radius Fractures. <i>Journal of Hand Surgery</i> , 2012, 37, 49. | 0.7 | 0 |
| 441 | Osteoprotection by semaphorin 3A. <i>Nature</i> , 2012, 485, 69-74. | 13.7 | 501 |
| 442 | Bisphosphonates in the Treatment of Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 487-506. | 1.2 | 51 |
| 443 | A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 2257-2276. | 1.3 | 291 |
| 444 | A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat. <i>Acta Neurochirurgica</i> , 2012, 154, 2215-2223. | 0.9 | 23 |
| 445 | Do bisphosphonates cause femoral insufficiency fractures?. <i>Journal of Orthopaedics and Traumatology</i> , 2012, 13, 171-177. | 1.0 | 15 |
| 446 | Management Strategy for Symptomatic Bisphosphonate-Associated Incomplete Atypical Femoral Fractures. <i>HSS Journal</i> , 2012, 8, 103-110. | 0.7 | 58 |
| 447 | The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. <i>Clinical Biochemistry</i> , 2012, 45, 907-919. | 0.8 | 49 |
| 448 | Histomorphometric and microarchitectural analyses using the 2mm bone marrow trephine in metastatic breast cancer patientsâ€™ preliminary results. <i>Journal of Bone Oncology</i> , 2012, 1, 69-73. | 1.0 | 7 |
| 449 | Seguridad de los bifosfonatos en el tratamiento de la osteoporosis. <i>Farmaceuticos De Atencion Primaria</i> , 2012, 10, 44-49. | 0.0 | 1 |
| 450 | Fractura patolÃ³gica atribuible a la terapia con bisfosfonatos. <i>Revista Colombiana De ReumatologÃ­a</i> , 2012, 19, 92-98. | 0.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data. <i>Journal of Clinical Densitometry</i> , 2012, 15, 92-102. | 0.5 | 33 |
| 452 | Femoral Fractures in Osteoporotic Patients on Bisphosphonates. A Case Report. <i>Journal of Clinical Densitometry</i> , 2012, 15, 380-384. | 0.5 | 6 |
| 453 | Early Initiation of Bisphosphonate Does Not Affect Healing and Outcomes of Volar Plate Fixation of Osteoporotic Distal Radial Fractures. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, 1729-1736. | 1.4 | 79 |
| 454 | Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. <i>Arthritis Research and Therapy</i> , 2012, 14, 220. | 1.6 | 37 |
| 455 | Antiresorptive therapies for osteoporosis: a clinical overview. <i>Nature Reviews Endocrinology</i> , 2012, 8, 81-91. | 4.3 | 164 |
| 456 | Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. <i>Bone</i> , 2012, 50, 1196-1200. | 1.4 | 27 |
| 457 | Relating micromechanical properties and mineral densities in severely suppressed bone turnover patients, osteoporotic patients, and normal subjects. <i>Bone</i> , 2012, 51, 114-122. | 1.4 | 29 |
| 458 | Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. <i>Bone</i> , 2012, 51, 524-527. | 1.4 | 78 |
| 459 | Atypical subtrochanteric fractures, bisphosphonates, blinded radiological review. <i>ANZ Journal of Surgery</i> , 2012, 82, 908-912. | 0.3 | 14 |
| 460 | Increasing Occurrence of Atypical Femoral Fractures Associated With Bisphosphonate Use. <i>Archives of Internal Medicine</i> , 2012, 172, 930-6. | 4.3 | 187 |
| 461 | Antiresorptives and Osteonecrosis of the Jaw. <i>Journal of Evidence-based Dental Practice</i> , 2012, 12, 233-247. | 0.7 | 86 |
| 462 | RNA therapeutics targeting osteoclast-mediated excessive bone resorption. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1341-1357. | 6.6 | 39 |
| 463 | Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude. <i>Homeopathy</i> , 2012, 101, 231-242. | 0.5 | 21 |
| 464 | Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: A case report and review on the prevention and treatment of bisphosphonate-related osteonecrosis of the jaw. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 113, 41-47. | 0.2 | 10 |
| 465 | Atypical femoral fracture after long-term alendronate treatment: Report of a case evidenced with magnetic resonance imaging. <i>Kaohsiung Journal of Medical Sciences</i> , 2012, 28, 555-558. | 0.8 | 10 |
| 467 | Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 286-292. | 1.8 | 43 |
| 468 | Low-energy spontaneous femoral fractures in patients with long-term bisphosphonate therapy. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2012, 22, 149-154. | 0.6 | 1 |
| 469 | Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. <i>Journal of Bone and Mineral Metabolism</i> , 2012, 30, 561-567. | 1.3 | 127 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 470 | Safety of Bisphosphonates. Rheumatic Disease Clinics of North America, 2012, 38, 681-705. | 0.8 | 24 |
| 471 | Spontaneous Incomplete transverse subtrochanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report. Journal of Medical Case Reports, 2012, 6, 272. | 0.4 | 9 |
| 472 | An Atypical Subtrochanteric Femoral Fracture in a Patient with Multiple Myeloma Received Zoledronic Acid: A Case Report. The Journal of the Korean Bone and Joint Tumor Society, 2012, 18, 99. | 0.0 | 0 |
| 473 | Atypical Subtrochanteric Femur Fracture in Patient with Metastatic Breast Cancer Treated with Zoledronic Acid. Journal of Breast Cancer, 2012, 15, 261. | 0.8 | 16 |
| 474 | Is It a Simple Stress Fracture or Bisphosphonate-related Atypical Fracture?. Journal of Bone Metabolism, 2012, 19, 129. | 0.5 | 1 |
| 475 | Clinical Analysis of Femur Shaft Insufficiency Fractures. Clinics in Orthopedic Surgery, 2012, 4, 227. | 0.8 | 6 |
| 476 | Present and Future Non-Surgical Therapeutic Strategies for the Management of Periodontal Diseases. , 0, , . | | 1 |
| 477 | Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back. Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15, 305. | 0.9 | 26 |
| 478 | Insufficiency Fracture of Ipsilateral Femur Neck in Patient Treated with Long Term Bisphosphonate Treatment - A Case Report -. Journal of Bone Metabolism, 2012, 19, 159. | 0.5 | 6 |
| 479 | Bisphosphonates and Bone. , 2012, , . | | 2 |
| 480 | Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. Journal of Bone and Mineral Research, 2012, 27, 825-834. | 3.1 | 96 |
| 481 | Low-energy fractures of the humeral shaft and bisphosphonate use. Journal of Bone and Mineral Research, 2012, 27, 1425-1431. | 3.1 | 8 |
| 482 | Pharmacology: Mechanism of Action of Bisphosphonates. , 2012, , 13-22. | | 0 |
| 483 | Use of Bisphosphonates in Osteoporosis. , 2012, , 49-57. | | 2 |
| 484 | Pharmacogenetics of Osteoporosis: What is the Evidence?. Current Osteoporosis Reports, 2012, 10, 221-227. | 1.5 | 15 |
| 485 | Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Current Medical Research and Opinion, 2012, 28, 475-491. | 0.9 | 39 |
| 486 | Bisphosphonate-associated Femur Fractures Have High Complication Rates with Operative Fixation. Clinical Orthopaedics and Related Research, 2012, 470, 2295-2301. | 0.7 | 124 |
| 487 | Drug-induced osteonecrosis of the jaw. Memo - Magazine of European Medical Oncology, 2012, 5, 57-62. | 0.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 488 | Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper. <i>Calcified Tissue International</i> , 2012, 90, 343-353. | 1.5 | 111 |
| 489 | Clinical presentation and pathological features of atypical subtrochanteric fracture after bisphosphonate treatment. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2012, 22, 417-421. | 0.6 | 2 |
| 490 | Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy. <i>Journal of Orthopaedic Science</i> , 2012, 17, 313-318. | 0.5 | 16 |
| 491 | Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 50. | 0.4 | 20 |
| 492 | The Effect of Long-term Alendronate Treatment on Cortical Thickness of the Proximal Femur. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 291-298. | 0.7 | 33 |
| 493 | Femoral Stress Fractures Associated With Long-term Bisphosphonate Treatment. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 759-765. | 0.7 | 33 |
| 494 | Update in Women's Health for the General Internist. <i>Journal of General Internal Medicine</i> , 2012, 27, 232-237. | 1.3 | 8 |
| 495 | Atypical diaphyseal femoral fractures—new aspects. <i>Skeletal Radiology</i> , 2012, 41, 75-81. | 1.2 | 15 |
| 496 | Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA). <i>Osteoporosis International</i> , 2012, 23, 433-443. | 1.3 | 118 |
| 497 | The impact of subtrochanteric fracture criteria on hip fracture classification. <i>Osteoporosis International</i> , 2012, 23, 743-750. | 1.3 | 15 |
| 498 | Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy. <i>BMC Research Notes</i> , 2013, 6, 11. | 0.6 | 10 |
| 499 | Atypical Femoral Fractures: An Orthopaedic Surgeon's Perspective. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013, 2, 91-98. | 0.7 | 3 |
| 500 | Bone mineralization: from tissue to crystal in normal and pathological contexts. <i>Osteoporosis International</i> , 2013, 24, 2153-2166. | 1.3 | 98 |
| 501 | Bone and vitamin D metabolism in HIV. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2013, 14, 119-125. | 2.6 | 17 |
| 502 | Osteoporosis in Premenopausal Women. , 2013, , 1101-1111. | | 2 |
| 503 | Atypical forearm fractures associated with long-term use of bisphosphonate. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2013, 133, 889-892. | 1.3 | 30 |
| 504 | Incidence and bone biopsy findings of atypical femoral fractures. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 585-594. | 1.3 | 23 |
| 505 | Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability. <i>Joint Bone Spine</i> , 2013, 80, 258-264. | 0.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 506 | We need a break: Bisphosphonates. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2013, 4, 11-14. | 0.6 | 0 |
| 507 | Faut-il donner des androgènes aux hommes ostéoporotiques?. <i>Revue Du Rhumatisme (Edition Tj ETQq1 1 0.784314 rgBT /Overlo</i> | 0.0 | 0 |
| 508 | Les bisphosphonates dans l'ostéoporose cortico-induite: efficacité et tolérance. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 123-129. | 0.0 | 0 |
| 509 | Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?. <i>Journal of Translational Medicine</i> , 2013, 11, 303. | 1.8 | 59 |
| 510 | Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. <i>Bone and Joint Journal</i> , 2013, 95-B, 1544-1550. | 1.9 | 29 |
| 511 | Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. <i>European Radiology</i> , 2013, 23, 222-227. | 2.3 | 30 |
| 512 | Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 162-168. | 3.1 | 130 |
| 513 | Incomplete Atypical Femoral Fractures: Assessing the Diagnostic Utility of DXA by Extending Femur Length. <i>Journal of Clinical Densitometry</i> , 2013, 16, 579-583. | 0.5 | 39 |
| 514 | What do we know about atypical fractures in patients on bisphosphonates treatment? A literature review using a case series. <i>Revista Española De Cirugía Ortopédica Y Traumatología</i> , 2013, 57, 95-105. | 0.1 | 0 |
| 515 | Proposed pathogenesis for atypical femoral fractures: Lessons from materials research. <i>Bone</i> , 2013, 55, 495-500. | 1.4 | 132 |
| 516 | Bisphosphonate Therapy and Atypical Fractures. <i>Orthopedic Clinics of North America</i> , 2013, 44, 137-151. | 0.5 | 34 |
| 518 | Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. <i>Bone</i> , 2013, 54, 1-7. | 1.4 | 35 |
| 519 | Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: A case report. <i>Bone</i> , 2013, 56, 406-409. | 1.4 | 31 |
| 520 | Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats. <i>Bone</i> , 2013, 53, 167-173. | 1.4 | 15 |
| 521 | Osteonecrosis. , 2013, , 249-282. | | 0 |
| 522 | Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1729-1737. | 3.1 | 213 |
| 523 | Antiestrogenic activity of echinacoside in ovariectomized rats. <i>Phytomedicine</i> , 2013, 20, 549-557. | 2.3 | 72 |
| 524 | Is androgen therapy indicated in men with osteoporosis?. <i>Joint Bone Spine</i> , 2013, 80, 459-465. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 525 | Osteonecrosis of the Jaw and Atypical Femoral Fractures. , 2013, , 1873-1908. | | 3 |
| 526 | Atypical Femoral fractures: A Review of the Literature. Current Osteoporosis Reports, 2013, 11, 179-187. | 1.5 | 24 |
| 527 | Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?. Aging Clinical and Experimental Research, 2013, 25, 605-609. | 1.4 | 18 |
| 528 | Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested caseâ€control study. BMJ Open, 2013, 3, e002084. | 0.8 | 19 |
| 529 | The Paradox of Preventionâ€Bilateral Atypical Subtrochanteric Fractures due to Bisphosphonates in Osteogenesis Imperfecta. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 871-872. | 1.8 | 23 |
| 530 | The Clinical Choice between Estrogen and Bisphosphonates to Prevent Bone Loss: Are Women Being Misled?. Women's Health, 2013, 9, 221-224. | 0.7 | 2 |
| 531 | Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested caseâ€control study. BMJ Open, 2013, 3, e002091. | 0.8 | 38 |
| 532 | Do bisphosphonates inhibit direct fracture healing?. Bone and Joint Journal, 2013, 95-B, 1263-1268. | 1.9 | 47 |
| 533 | Efficacy and Safety of Echinacoside in a Rat Osteopenia Model. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10. | 0.5 | 19 |
| 534 | Bisphosphonates and Nonhealing Femoral Fractures: Analysis of the FDA Adverse Event Reporting System (FAERS) and International Safety Efforts. Journal of Bone and Joint Surgery - Series A, 2013, 95, 297-307. | 1.4 | 100 |
| 535 | Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , . | | 5 |
| 536 | Epidemiology, radiology and histology of atypical femoral fractures. Monthly Notices of the Royal Astronomical Society: Letters, 2013, 84, 1-26. | 1.2 | 44 |
| 537 | Ultrastructural and immunohistochemical study of early repair of alveolar sockets after the extraction of molars from alendronateâ€treated rats. Microscopy Research and Technique, 2013, 76, 633-640. | 1.2 | 18 |
| 538 | Burden of bisphosphonateâ€associated femoral fractures. ANZ Journal of Surgery, 2013, 83, 175-181. | 0.3 | 33 |
| 539 | Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate. Canadian Journal of Physiology and Pharmacology, 2013, 91, 380-385. | 0.7 | 39 |
| 540 | âf“ã,1ãf•ã,©ã,1ãf•ã,©ãfãf1/4ãf^è£1/2ã%ã†...æœãŠç™,ãã«ç”ŸããŸã;ããšè...¿éã”éãžã”šãž<éã”æšã”ã”1ã¾ã. Orthopedics & Traumatology | | |
| 541 | éžã”šãžãšè...¿éã”éã”æšã”ã”æ²»ç™,çμCEé“. Orthopedics & Traumatology, 2013, 62, 312-315. | 0.0 | 0 |
| 542 | âf“ã,1ãf•ã,©ã,1ãf•ã,©ãfãf1/4ãf^è£1/2ã%œã•æœŸæšã”ãžã¾CEã«ç”ŸããŸãéžã”šãžãšè...¿éã”éã”æšã”ã”3ã¾ã. Orthopedics & Traumatology | | |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 543 | Orthopedics & Traumatology, 2013, 62, 18. | | |
| 544 | NCCN Task Force Report: Bone Health in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, S-1-S-50. | 2.3 | 245 |
| 545 | Diagnosis and treatment of bisphosphonate-induced atypical femoral fractures. Aging Health, 2013, 9, 451-457. | 0.3 | 1 |
| 546 | Orthopedics & Traumatology, 2013, 62, 18. | | |
| 547 | Audit of atypical hip fractures at the Royal Berkshire Hospital. Clinical Audit, 2013, , 91. | 0.4 | 1 |
| 548 | Effect of alendronate on bone remodeling around implant in the rat. Journal of Advanced Prosthodontics, 2013, 5, 374. | 1.1 | 6 |
| 549 | Case of femoral diaphyseal stress fracture after long-term risedronate administration diagnosed by iliac bone biopsy. Therapeutics and Clinical Risk Management, 2013, 9, 191. | 0.9 | 3 |
| 550 | A Case of an Unusual Subtrochanteric Fracture in a Patient Receiving Denosumab. Endocrine Practice, 2013, 19, e64-e68. | 1.1 | 54 |
| 551 | Atypical femoral fractures. Clinical Cases in Mineral and Bone Metabolism, 2013, 10, 30-3. | 1.0 | 10 |
| 552 | Acute Postoperative Bisphosphonate-Associated Atypical Periprosthetic Femoral Fracture. JBJS Case Connector, 2013, 3, e85. | 0.1 | 9 |
| 553 | Atypical Subtrochanteric Fracture Through a Cephalomedullary Implant. JBJS Case Connector, 2013, 3, e62. | 0.1 | 2 |
| 554 | Supplementation with Fish Oil and Genistein, Individually or in Combination, Protects Bone against the Adverse Effects of Methotrexate Chemotherapy in Rats. PLoS ONE, 2013, 8, e71592. | 1.1 | 29 |
| 555 | Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo, 2013, 65, 143-66. | 0.4 | 34 |
| 556 | Effects of a 'Drug Holiday' on Bone Mineral Density and Bone Turnover Marker During Bisphosphonate Therapy. Journal of Bone Metabolism, 2013, 20, 31. | 0.5 | 9 |
| 557 | An NMR Metabolomic Study on the Effect of Alendronate in Ovariectomized Mice. PLoS ONE, 2014, 9, e106559. | 1.1 | 28 |
| 558 | The Roles of Small GTPases in Osteoclast Biology. , 2014, 03, . | | 26 |
| 559 | Fracturas Femorais Atípicas e o Tratamento com Bifosfonatos: Um Factor de Risco?. Acta Medica Portuguesa, 2014, 27, 704-709. | 0.2 | 5 |
| 560 | The safety of osteoporosis medication. South African Medical Journal, 2014, 104, 279. | 0.2 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 561 | Semaphorin 3A. <i>Cell Adhesion and Migration</i> , 2014, 8, 5-10. | 1.1 | 50 |
| 562 | The Indispensable Value of Clinical Trials in the Modernization of Traditional Chinese Medicine: 12 Years' Experience at CUHK and Future Perspectives. <i>The American Journal of Chinese Medicine</i> , 2014, 42, 587-604. | 1.5 | 17 |
| 563 | Atypical Femur Fractures: A Review. <i>Current Osteoporosis Reports</i> , 2014, 12, 446-453. | 1.5 | 17 |
| 564 | Alterations in Collagen and Mineral Nanostructure Observed in Osteoporosis and Pharmaceutical Treatments Using Simultaneous Small- and Wide-Angle X-ray Scattering. <i>Calcified Tissue International</i> , 2014, 95, 446-456. | 1.5 | 21 |
| 565 | Effect of Cervus and Cucumis Peptides on Osteoblast Activity and Fracture Healing in Osteoporotic Bone. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-10. | 0.5 | 6 |
| 566 | Histology of 8 atypical femoral fractures. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2014, 85, 280-286. | 1.2 | 64 |
| 567 | Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer. <i>Acta Oncologica</i> , 2014, 53, 547-556. | 0.8 | 1 |
| 568 | BONE HISTOLOGY OF PATIENTS WITH ALENDRONATE-MEDIATED FRACTURED BONE – A NEW ENTITY OF ATYPICAL OSTEOMALACIA. <i>Journal of Musculoskeletal Research</i> , 2014, 17, 1450011. | 0.1 | 0 |
| 569 | Bisphosphonate-associated atypical femoral fractures and one-year mortality. <i>Upsala Journal of Medical Sciences</i> , 2014, 119, 357-358. | 0.4 | 5 |
| 570 | Bilateral Atypical Femoral Fractures in a Patient with Multiple Myeloma Treated with Intravenous Bisphosphonate Therapy. <i>Case Reports in Orthopedics</i> , 2014, 2014, 1-4. | 0.1 | 3 |
| 571 | Clinician approach to diagnosis of stress fractures including bisphosphonate-associated fractures. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 99-105. | 0.2 | 24 |
| 572 | Bisphosphonate-Associated Subtrochanteric Femoral Fracture with Profound Proximal Cortical Thickening and Canal Narrowing Requiring Blade-Plate Fixation. <i>JBJS Case Connector</i> , 2014, 4, e87. | 0.1 | 2 |
| 573 | Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 349-353. | 0.7 | 10 |
| 574 | Bisphosphonates and Risk of Subtrochanteric, Femoral Shaft, and Atypical Femur Fracture: Sensitivity and Trim and Fill Studies. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 117-122. | 0.3 | 5 |
| 575 | The Transcription Factor T-box 3 Regulates Colony-stimulating Factor 1-dependent Jun Dimerization Protein 2 Expression and Plays an Important Role in Osteoclastogenesis. <i>Journal of Biological Chemistry</i> , 2014, 289, 6775-6790. | 1.6 | 11 |
| 576 | The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab. <i>Gynecological Endocrinology</i> , 2014, 30, 403-408. | 0.7 | 13 |
| 577 | Propagation of Bisphosphonate-Related Femoral Stress Fractures Despite Femoral Nailing. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2014, 5, 14-17. | 0.6 | 11 |
| 578 | Bisphosphonates and Hip and Nontraumatic Subtrochanteric Femoral Fractures in the Veterans Health Administration. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 357-362. | 0.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 579 | Atypical Femur Fractures. Journal of Orthopaedic Trauma, 2014, 28, S36-S42. | 0.7 | 10 |
| 580 | Bisphosphonate-Associated Fractures of the Femur. Journal of Orthopaedic Trauma, 2014, 28, 433-438. | 0.7 | 20 |
| 581 | Better Osteoporotic Fracture Healing with Sintered Dicalcium Pyrophosphate (SDCP) Treatment. Journal of Histochemistry and Cytochemistry, 2014, 62, 565-576. | 1.3 | 3 |
| 582 | Atypical femoral fractures in elderly women. Bone and Joint Journal, 2014, 96-B, 1035-1040. | 1.9 | 26 |
| 583 | Acute Nontraumatic Clavicle Fracture Associated with Long-Term Bisphosphonate Therapy. Case Reports in Orthopedics, 2014, 2014, 1-3. | 0.1 | 5 |
| 584 | Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2014, 17, 44-49. | 0.9 | 7 |
| 585 | Pharmacokinetics and bone resorption evaluation of a novel <sc>C</sc>athepsin <sc>K</sc> inhibitor (<sc>VEL</sc>â€230) in healthy adult horses. Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, 556-564. | 0.6 | 6 |
| 586 | A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy. Bone, 2014, 64, 183-186. | 1.4 | 32 |
| 587 | Symptomatic atypical femoral fractures are related to underlying hip geometry. Bone, 2014, 63, 1-6. | 1.4 | 77 |
| 588 | Low-energy femoral stress fracture in long-term bisphosphonate use: conservative and surgical treatment. European Orthopaedics and Traumatology, 2014, 5, 15-23. | 0.1 | 0 |
| 589 | Healing Delayed But Generally Reliable After Bisphosphonate-associated Complete Femur Fractures Treated with IM Nails. Clinical Orthopaedics and Related Research, 2014, 472, 2728-2734. | 0.7 | 108 |
| 590 | Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporosis International, 2014, 25, 349-357. | 1.3 | 26 |
| 591 | Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension. Journal of Bone and Mineral Research, 2014, 29, 2051-2056. | 3.1 | 56 |
| 592 | Additive effects of antiresorptive agents and exercise on lumbar spine bone mineral density in adults with low bone mass: a meta-analysis. Osteoporosis International, 2014, 25, 1585-1594. | 1.3 | 11 |
| 593 | Review: Epidemiology and Pathophysiology of Atypical Femur Fractures. Current Osteoporosis Reports, 2014, 12, 65-73. | 1.5 | 10 |
| 594 | Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases. Osteoporosis International, 2014, 25, 993-997. | 1.3 | 18 |
| 595 | Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures. Biologics in Therapy, 2014, 4, 73-79. | 1.8 | 26 |
| 596 | Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology, 2014, 53, 19-31. | 0.9 | 122 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 597 | Disorders of mineral homeostasis in children and adolescents. , 2014, , 734-845.e1. | | 7 |
| 598 | Bone Quality: The Determinants of Bone Strength and Fragility. Sports Medicine, 2014, 44, 37-53. | 3.1 | 287 |
| 600 | Bifosfonati e terapia ortodontica: implicazioni cliniche. Dental Cadmos, 2014, 82, 614-621. | 0.0 | 0 |
| 601 | Effect of ONO-5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2-Year Results From the OCEAN Study. Journal of Bone and Mineral Research, 2014, 29, 458-466. | 3.1 | 64 |
| 602 | Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: Mechanical analysis by the CT-based finite element method. Injury, 2014, 45, 1764-1771. | 0.7 | 64 |
| 603 | The fracture sites of atypical femoral fractures are associated with the weight-bearing lower limb alignment. Bone, 2014, 66, 105-110. | 1.4 | 72 |
| 604 | Development, validation and characterization of a novel mouse model of Adynamic Bone Disease (ABD). Bone, 2014, 68, 57-66. | 1.4 | 8 |
| 605 | Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone and Joint Journal, 2014, 96-B, 658-664. | 1.9 | 89 |
| 606 | Relevance of Wnt signaling for osteoanabolic therapy. Molecular and Cellular Therapies, 2014, 2, 22. | 0.2 | 6 |
| 607 | An Atypical Femoral Fracture in a Patient on Long-term Alendronate Therapy. Journal of Musculoskeletal Pain, 2014, 22, 322-326. | 0.3 | 1 |
| 608 | Stress fracture of the bowed femoral shaft is another cause of atypical femoral fracture in elderly Japanese: a case series. Journal of Orthopaedic Science, 2014, 19, 579-586. | 0.5 | 65 |
| 609 | Atypical femoral fractures in association with bisphosphonate therapy: a case series. Emergency Radiology, 2014, 21, 557-562. | 1.0 | 8 |
| 610 | Bisphosphonate Drug Holidays and Fall Prevention in the Reduction of Postmenopausal Fractures. American Journal of Lifestyle Medicine, 2014, 8, 167-170. | 0.8 | 0 |
| 611 | Atypical Femoral Fractures, Bisphosphonates, and Mechanical Stress. Current Osteoporosis Reports, 2014, 12, 189-193. | 1.5 | 30 |
| 612 | Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?. Drug Discovery Today, 2014, 19, 312-319. | 3.2 | 35 |
| 613 | Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone, 2014, 59, 37-43. | 1.4 | 103 |
| 614 | éâ»»£è-éŽâ%°æŠ`â~ŕ1/4`SSBT1/4%oã«ã,^ã,«âšè...jéâ`è»«ãâ,«éâ`æŠ`ã®1ã³/4«. Orthopedics & Traumatology, 2014, 63, 773-778 | | |
| 615 | The Therapeutic Potential of Anti-Interleukin-20 Monoclonal Antibody. Cell Transplantation, 2014, 23, 631-639. | 1.2 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 616 | Successful Spinal Fixation Surgery Following Teriparatide Treatment in an Adolescent Boy with Severe Osteoporosis and Progressive Kyphoscoliosis. <i>JBJS Case Connector</i> , 2014, 4, e89. | 0.1 | 0 |
| 617 | ájáéžá@šázášè...jé"é"æŠ-á¼CEã«ç"Ÿã-ãŸã;ášè...jé"ç-2áŠ'é"æŠ-ã®1ã¾¼«. <i>Orthopedics & Traumatology</i> , 2014, 68p779-783. | | |
| 618 | Oral Bisphosphonate-Related Mandible Fracture. <i>Journal of Craniofacial Surgery</i> , 2014, 25, 709-711. | 0.3 | 3 |
| 619 | Bone Density Screening and Re-screening in Postmenopausal Women and Older Men. <i>Current Osteoporosis Reports</i> , 2015, 13, 390-398. | 1.5 | 20 |
| 620 | Osteoporosis: the emperor has no clothes. <i>Journal of Internal Medicine</i> , 2015, 277, 662-673. | 2.7 | 44 |
| 621 | Atypical Vancouver Type-C Periprosthetic Fracture Complicated by Nonunion. <i>JBJS Case Connector</i> , 2015, 5, e44. | 0.1 | 10 |
| 622 | Bilateral Atypical Femoral Fracture in a Man on Long-Term Bisphosphonate and Glucocorticoid Therapy. <i>JBJS Case Connector</i> , 2015, 5, e36. | 0.1 | 3 |
| 623 | ãf"ã,1ãf>ã,1ãf>ãfãf¼ãf^ã†...æœã,ã®é"Pagetç-...æ,£è€...ã«ç"Ÿã-ãŸãéžá@šázášè...jé"è»çãã,é"æŠ-ã®1ã¾¼«. <i>Orthopedics & Traumatology</i> | | |
| 624 | Effect of ibandronate on bending strength and toughness of rodent cortical bone. <i>Bone and Joint Research</i> , 2015, 4, 99-104. | 1.3 | 5 |
| 625 | Obliteration of the medullary canal in an atypical bisphosphonate-related femoral fracture. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014205439-bcr2014205439. | 0.2 | 1 |
| 627 | The effects of zoledronate on the survival and function of human osteoblast-like cells. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 355. | 0.8 | 16 |
| 628 | Bilateral Femoral Neck Insufficiency Fractures after Use of a Long-term Anti-resorptive Drug Therapy for Osteoporosis: A Case Report. <i>Hip and Pelvis</i> , 2015, 27, 115-119. | 0.6 | 8 |
| 629 | Radiographic Changes and Fracture in Patients Having Received Bisphosphonate Therapy for 5 Years at a Single Institution. <i>Military Medicine</i> , 2015, 180, 1214-1218. | 0.4 | 6 |
| 630 | Periprosthetic Insufficiency Fracture around Radiographically Loose Cemented Stem: A Report of Two Cases. <i>Hip and Pelvis</i> , 2015, 27, 183-186. | 0.6 | 7 |
| 631 | Atypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research. <i>Journal of Bone Metabolism</i> , 2015, 22, 87. | 0.5 | 17 |
| 632 | Pathogenesis, Management and Prevention of Atypical Femoral Fractures. <i>Journal of Bone Metabolism</i> , 2015, 22, 1. | 0.5 | 21 |
| 633 | Atypical femur fractures associated with bisphosphonates: from prodrome to resolution. <i>Rheumatology Reports</i> , 2015, 7, . | 0.1 | 1 |
| 634 | The Effect of Alendronate Loaded Biphasic Calcium Phosphate Scaffolds on Bone Regeneration in a Rat Tibial Defect Model. <i>International Journal of Molecular Sciences</i> , 2015, 16, 26738-26753. | 1.8 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 635 | Combined Effect of a Locking Plate and Teriparatide for Incomplete Atypical Femoral Fracture: Two Case Reports of Curved Femurs. <i>Case Reports in Orthopedics</i> , 2015, 2015, 1-5. | 0.1 | 12 |
| 636 | Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures. <i>Hip and Pelvis</i> , 2015, 27, 9-16. | 0.6 | 2 |
| 638 | Consumption of vitamin D2 enhanced mushrooms is associated with improved bone health. <i>Journal of Nutritional Biochemistry</i> , 2015, 26, 696-703. | 1.9 | 25 |
| 639 | Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 185-193. | 1.1 | 67 |
| 640 | Association between alendronate and atypical femur fractures: a meta-analysis. <i>Endocrine Connections</i> , 2015, 4, 58-64. | 0.8 | 12 |
| 641 | High revision rate but good healing capacity of atypical femoral fractures. A comparison with common shaft fractures. <i>Injury</i> , 2015, 46, 2468-2473. | 0.7 | 42 |
| 642 | Removal of pamidronate from bone in rats using systemic and local chelation. <i>Archives of Oral Biology</i> , 2015, 60, 1699-1707. | 0.8 | 9 |
| 643 | Bcl6 promotes osteoblastogenesis through Stat1 inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2015, 457, 451-456. | 1.0 | 22 |
| 644 | Atypical Femoral Fractures: A Teaching Perspective. <i>Canadian Association of Radiologists Journal</i> , 2015, 66, 102-107. | 1.1 | 15 |
| 645 | Emerging role of alpha-lipoic acid in the prevention and treatment of bone loss. <i>Nutrition Reviews</i> , 2015, 73, 116-125. | 2.6 | 17 |
| 646 | Questioning the association between bisphosphonates and atypical femoral fractures. <i>Annals of the New York Academy of Sciences</i> , 2015, 1335, 1-9. | 1.8 | 16 |
| 647 | Bisphosphonates and their influence on fracture healing: a systematic review. <i>Osteoporosis International</i> , 2015, 26, 1251-1260. | 1.3 | 78 |
| 648 | Risk of atypical femoral fracture during and after bisphosphonate use. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2015, 86, 100-107. | 1.2 | 153 |
| 649 | The Standardized BHH10 Extract, a Combination of <i>Astragalus membranaceus</i> , <i>Cinnamomum cassia</i> , and <i>Phellodendron amurense</i> , Reverses Bone Mass and Metabolism in a Rat Model of Postmenopausal Osteoporosis. <i>Phytotherapy Research</i> , 2015, 29, 30-39. | 2.8 | 13 |
| 650 | Right thigh pain. <i>Skeletal Radiology</i> , 2015, 44, 715-716. | 1.2 | 0 |
| 651 | Atypical fracture in a child with osteogenesis imperfecta. <i>Joint Bone Spine</i> , 2015, 82, 287-288. | 0.8 | 8 |
| 652 | Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. <i>Osteoporosis International</i> , 2015, 26, 327-337. | 1.3 | 7 |
| 653 | Régression spontanée d'un pneumorachis cervicothoracique extensif. <i>Revue Du Rhumatisme (Edition) Tj</i> 0,0 1 0,784314 | 0,0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 654 | Prostaglandin Dependent Control of an Endogenous Estrogen Receptor Agonist by Osteoblasts. <i>Journal of Cellular Physiology</i> , 2015, 230, 1104-1114. | 2.0 | 2 |
| 656 | Bisphosphonates and glucocorticoid-induced osteoporosis: cons. <i>Endocrine</i> , 2015, 49, 628-634. | 1.1 | 20 |
| 657 | Bisphosphonates vs. Atypical Femur Fractures - Influence on Bone Resorption. <i>Key Engineering Materials</i> , 2015, 638, 296-300. | 0.4 | 1 |
| 658 | Atypical Fractures of the Femur: Evaluation and Treatment. <i>JBJS Reviews</i> , 2015, 3, . | 0.8 | 8 |
| 659 | BMP-4 increases activin Agene expression during osteogenic differentiation of mouse embryonic stem cells. <i>Growth Factors</i> , 2015, 33, 133-138. | 0.5 | 5 |
| 660 | Atypical Subtrochanteric Femoral Fracture Below an Arthritic Hip. <i>JBJS Case Connector</i> , 2015, 5, e1. | 0.1 | 2 |
| 661 | Increased risk for atypical fractures associated with bisphosphonate use. <i>Family Practice</i> , 2015, 32, 276-281. | 0.8 | 17 |
| 662 | Bisphosphonates and Atypical Femoral Fractures. <i>Journal for Nurse Practitioners</i> , 2015, 11, 389-396. | 0.4 | 1 |
| 663 | Long-Term Treatment with Eldecalcitol (1 α , 25-Dihydroxy-2 β - (3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnover and Leads to Prevention of Bone Loss and Bone Fragility in Ovariectomized Rats. <i>Calcified Tissue International</i> , 2015, 96, 45-55. | 1.5 | 15 |
| 664 | Right thigh pain. <i>Skeletal Radiology</i> , 2015, 44, 763-764. | 1.2 | 1 |
| 665 | Prodromal Symptoms in Patients with Bisphosphonate-Associated Atypical Fractures of the Femur. <i>Journal of Bone and Mineral Metabolism</i> , 2015, 33, 516-522. | 1.3 | 14 |
| 666 | Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. <i>Bone</i> , 2015, 81, 352-363. | 1.4 | 58 |
| 667 | Management of bone disease in women after breast cancer. <i>Climacteric</i> , 2015, 18, 47-55. | 1.1 | 18 |
| 668 | Catastrophic antiphospholipid syndrome presenting with bilateral massive adrenal haemorrhage. A case report. <i>Joint Bone Spine</i> , 2015, 82, 288-289. | 0.8 | 8 |
| 669 | Serum pentosidine levels after 3 years of bisphosphonate treatment in post-menopausal osteoporotic women. <i>Endocrine Research</i> , 2015, 40, 172-176. | 0.6 | 6 |
| 670 | Surgical Difficulties and Complications in the Treatment of Bisphosphonate-related Proximal Femur Fractures. <i>Journal of Orthopaedics, Trauma and Rehabilitation</i> , 2015, 19, 83-88. | 0.1 | 3 |
| 671 | Bisphosphonates for the prevention and treatment of osteoporosis. <i>BMJ, The</i> , 2015, 351, h3783. | 3.0 | 122 |
| 672 | Atypical Femur Fractures Associated With Diphosphonate Use. <i>Journal of the American Academy of Orthopaedic Surgeons, The</i> , 2015, 23, 550-557. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 673 | Effects of the combined extracts of Herba Epimedii and Fructus Ligustri Lucidi on bone mineral content and bone turnover in osteoporotic rats. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 112. | 3.7 | 25 |
| 674 | The osteogenic effects of swimming, jumping, and vibration on the protection of bone quality from disuse bone loss. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2015, 25, 390-397. | 1.3 | 29 |
| 675 | A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid. <i>Breast Cancer</i> , 2015, 22, 90-94. | 1.3 | 9 |
| 677 | Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. <i>Osteoporosis International</i> , 2015, 26, 431-441. | 1.3 | 56 |
| 678 | Cortical Thickness of the Femur and Long-Term Bisphosphonate Use. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 225-231. | 3.1 | 26 |
| 679 | Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2015, 25, 181-187. | 0.6 | 8 |
| 680 | The incidence of and risk factors for developing atypical femoral fractures in Japan. <i>Journal of Bone and Mineral Metabolism</i> , 2015, 33, 311-318. | 1.3 | 55 |
| 681 | A rare case of a bisphosphonate-related femoral diaphyseal fracture occurring below a previously fixed compression hip screw (CHS) plate. <i>Journal of Orthopaedic Science</i> , 2015, 20, 559-562. | 0.5 | 5 |
| 682 | Atypical ulnar fracture associated with long-term bisphosphonate use. <i>Journal of Orthopaedic Science</i> , 2015, 20, 1132-1135. | 0.5 | 22 |
| 683 | Treatment of a Patient With Implant Failure and Jaw Osteonecrosis: Successful Retreatment Using Implants. <i>Journal of Oral Implantology</i> , 2016, 42, 82-85. | 0.4 | 1 |
| 684 | Influence of Early Bisphosphonate Administration for Fracture Healing in Patients with Osteoporotic Proximal Humerus Fractures. <i>Clinics in Orthopedic Surgery</i> , 2016, 8, 437. | 0.8 | 25 |
| 685 | Atypical periprosthetic acetabular fracture in long-term alendronate therapy. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016, 13, 209-213. | 1.0 | 12 |
| 686 | Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents. <i>Journal of Bone Metabolism</i> , 2016, 23, 85. | 0.5 | 0 |
| 687 | The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials. <i>BioMed Research International</i> , 2016, 2016, 1-10. | 0.9 | 37 |
| 688 | Atypical Complete Femoral Fractures Associated with Bisphosphonate Use or Not Associated with Bisphosphonate Use: Is There a Difference?. <i>BioMed Research International</i> , 2016, 2016, 1-8. | 0.9 | 4 |
| 689 | Impact of Soft Tissue Pathophysiology in the Development and Maintenance of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). <i>Dentistry Journal</i> , 2016, 4, 36. | 0.9 | 13 |
| 690 | MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 349. | 1.8 | 77 |
| 691 | Study of Atypical Femoral Fracture Cases Coupled in a Multicenter Study. <i>Journal of UOEH</i> , 2016, 38, 207-214. | 0.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 692 | Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use. <i>Journal of Orthopaedic Trauma</i> , 2016, 30, 177-181. | 0.7 | 57 |
| 693 | Recurrent Proximal Femur Fractures in a Teenager With Osteogenesis Imperfecta on Continuous Bisphosphonate Therapy: Are We Overtreating?. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1449-1454. | 3.1 | 33 |
| 694 | Zeitlicher Verlauf der avaskulären Nekrose des Hüftkopfes bei Patienten mit Pemphigus vulgaris. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1016-1022. | 0.4 | 0 |
| 695 | Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women. <i>BMC Women's Health</i> , 2016, 16, 59. | 0.8 | 14 |
| 696 | Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis. <i>Scientific Reports</i> , 2016, 6, 24339. | 1.6 | 24 |
| 697 | Management of atypical femoral fracture: a scoping review and comprehensive algorithm. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 227. | 0.8 | 45 |
| 698 | Naringin ameliorates bone loss induced by sciatic neurectomy and increases Semaphorin 3A expression in denervated bone. <i>Scientific Reports</i> , 2016, 6, 24562. | 1.6 | 31 |
| 699 | Femoral Fractures Following Long-term Bisphosphonate Use. <i>Orthopedics</i> , 2016, 39, e1036-e1040. | 0.5 | 3 |
| 700 | Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy. <i>Journal of Bone and Joint Surgery - Series A</i> , 2016, 98, 1978-1987. | 1.4 | 55 |
| 701 | Bisphosphonates and atypical femoral fractures. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 430-434. | 1.2 | 10 |
| 702 | Musculoskeletal injuries in the elderly. , 2016, , 462-476. | | 0 |
| 703 | The Relationship of Parathyroidectomy and Bisphosphonates With Fracture Risk in Primary Hyperparathyroidism. <i>Annals of Internal Medicine</i> , 2016, 164, 715. | 2.0 | 91 |
| 704 | Surgical tips of intramedullary nailing in severely bowed femurs in atypical femur fractures: Simulation with 3D printed model. <i>Injury</i> , 2016, 47, 1318-1324. | 0.7 | 57 |
| 705 | The advantages of tomosynthesis for evaluating bisphosphonate-related atypical femur fractures compared to radiography. <i>Skeletal Radiology</i> , 2016, 45, 615-623. | 1.2 | 11 |
| 707 | Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy. <i>Biochemical Pharmacology</i> , 2016, 117, 10-19. | 2.0 | 50 |
| 708 | Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database. <i>Annals of Pharmacotherapy</i> , 2016, 50, 616-624. | 0.9 | 19 |
| 709 | <i>Pueraria mirifica</i> alleviates cortical bone loss in naturally menopausal monkeys. <i>Journal of Endocrinology</i> , 2016, 231, 121-133. | 1.2 | 6 |
| 710 | Proximal femoral reconstruction for failed internal fixation of a bisphosphonate-related femur fracture. <i>Arthroplasty Today</i> , 2016, 2, 153-156. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 711 | Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients. <i>Injury</i> , 2016, 47, 2484-2489. | 0.7 | 8 |
| 712 | Clinical features of atypical femur fracture. <i>Osteoporosis and Sarcopenia</i> , 2016, 2, 244-249. | 0.7 | 5 |
| 713 | Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates. <i>Osteoporosis International</i> , 2016, 27, 2681-2688. | 1.3 | 20 |
| 714 | Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 16-35. | 3.1 | 491 |
| 715 | Atypical femoral fractures and current management. <i>Journal of Orthopaedic Translation</i> , 2016, 7, 7-22. | 1.9 | 13 |
| 716 | Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation. <i>Bone</i> , 2016, 91, 148-151. | 1.4 | 23 |
| 717 | A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone. <i>Scientific Reports</i> , 2016, 6, 26033. | 1.6 | 52 |
| 718 | Wedelolactone enhances osteoblastogenesis by regulating Wnt/ β 2-catenin signaling pathway but suppresses osteoclastogenesis by NF- κ B/c-fos/NFATc1 pathway. <i>Scientific Reports</i> , 2016, 6, 32260. | 1.6 | 36 |
| 719 | Atypical Fractures Following Bisphosphonate Therapy. <i>Seminars in Musculoskeletal Radiology</i> , 2016, 20, 376-381. | 0.4 | 8 |
| 720 | Temporal course of avascular femoral head necrosis in patients with pemphigus vulgaris. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1016-1021. | 0.4 | 2 |
| 721 | Insufficient Penetration of Bone Cement Into the Trabecular Bone. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 616-618. | 1.1 | 15 |
| 722 | Bilateral prophylactic femoral intramedullary fixation for symptomatic bisphosphonate lesions. <i>Current Orthopaedic Practice</i> , 2016, 27, 553-556. | 0.1 | 0 |
| 723 | Adynamic Bone Decreases Bone Toughness During Aging by Affecting Mineral and Matrix. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 369-379. | 3.1 | 28 |
| 724 | Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 767-776. | 3.1 | 60 |
| 725 | Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 329-348. | 1.2 | 2 |
| 726 | Acute and Stress-related Injuries of Bone and Cartilage: Pertinent Anatomy, Basic Biomechanics, and Imaging Perspective. <i>Radiology</i> , 2016, 280, 21-38. | 3.6 | 105 |
| 727 | Rethinking end-points for bone-targeted therapy in advanced cancer. <i>European Journal of Cancer</i> , 2016, 63, 105-109. | 1.3 | 6 |
| 728 | The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. <i>Osteoporosis International</i> , 2016, 27, 1217-1225. | 1.3 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 729 | Factors related to curved femur in elderly Japanese women. <i>Upsala Journal of Medical Sciences</i> , 2016, 121, 170-173. | 0.4 | 11 |
| 730 | Preclinical studies and clinical evaluation of compounds from the genus <i>Epimedium</i> for osteoporosis and bone health. , 2016, 162, 188-205. | | 101 |
| 731 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. <i>Osteoporosis International</i> , 2016, 27, 1701-1708. | 1.3 | 12 |
| 732 | Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 807-834. | 1.8 | 38 |
| 733 | Osteoclast TGF- β 2 Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 76-85. | 3.1 | 73 |
| 734 | Atypical fractures, a biased perspective. <i>Injury</i> , 2016, 47, S28-S30. | 0.7 | 4 |
| 735 | Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw. <i>Clinical Oral Investigations</i> , 2016, 20, 2251-2258. | 1.4 | 23 |
| 736 | Audit of Atypical Femoral Fractures and a Description of Some of Their Features. <i>Canadian Association of Radiologists Journal</i> , 2016, 67, 69-75. | 1.1 | 7 |
| 737 | Compliance with established guidelines for the radiological reporting of atypical femoral fractures. <i>British Journal of Radiology</i> , 2016, 89, 20150443. | 1.0 | 12 |
| 738 | Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys. <i>Bone</i> , 2016, 86, 43-52. | 1.4 | 10 |
| 739 | Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy. <i>Osteoporosis International</i> , 2016, 27, 833-836. | 1.3 | 6 |
| 741 | In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss. <i>Osteoporosis International</i> , 2016, 27, 797-808. | 1.3 | 8 |
| 742 | Atypical Femoral Fractures—Ongoing and History of Bone-Specific Therapy, Concomitant Diseases, Medications, and Survival. <i>Journal of Clinical Densitometry</i> , 2016, 19, 359-367. | 0.5 | 8 |
| 743 | Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. <i>Clinical Rheumatology</i> , 2016, 35, 205-212. | 1.0 | 4 |
| 744 | Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: A systematic review. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 83-91. | 1.5 | 42 |
| 745 | Spinal Compression Fracture Management. <i>Global Spine Journal</i> , 2017, 7, 71-82. | 1.2 | 35 |
| 746 | Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases. <i>Journal of Bone and Mineral Metabolism</i> , 2017, 35, 209-214. | 1.3 | 37 |
| 747 | Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 29. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 748 | Intrinsic material property differences in bone tissue from patients suffering low-trauma osteoporotic fractures, compared to matched non-fracturing women. <i>Bone</i> , 2017, 97, 233-242. | 1.4 | 24 |
| 749 | Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity. <i>Scientific Reports</i> , 2017, 7, 36129. | 1.6 | 50 |
| 750 | Complex regional pain syndrome: a recent update. <i>Burns and Trauma</i> , 2017, 5, 2. | 2.3 | 106 |
| 751 | Bone Structure and Turnover Status in Postmenopausal Women with Atypical Femur Fracture After Prolonged Bisphosphonate Therapy. <i>Calcified Tissue International</i> , 2017, 100, 235-243. | 1.5 | 13 |
| 752 | Atypical femoral shaft fractures secondary to long-term bisphosphonate therapy. <i>Journal of Orthopaedics</i> , 2017, 14, 226-230. | 0.6 | 7 |
| 753 | Atypical femoral fractures related to bisphosphonate treatment. <i>Bone and Joint Journal</i> , 2017, 99-B, 295-302. | 1.9 | 102 |
| 754 | A new contralateral atypical femoral fracture despite sequential therapy with teriparatide and strontium ranelate. <i>Bone Reports</i> , 2017, 6, 34-37. | 0.2 | 13 |
| 755 | Surgical outcome of intramedullary nailing in patients with complete atypical femoral fracture: A multicenter retrospective study. <i>Injury</i> , 2017, 48, 941-945. | 0.7 | 38 |
| 756 | Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. <i>Scientific Reports</i> , 2017, 7, 43399. | 1.6 | 56 |
| 757 | Long-term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1165-1173. | 3.1 | 50 |
| 758 | Intramedullary Nail Fixation of Atypical Femur Fractures With Bone Marrow Aspirate Concentrate Leads to Faster Union: A Case-Control Study. <i>Journal of Orthopaedic Trauma</i> , 2017, 31, 358-362. | 0.7 | 24 |
| 759 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. <i>Journal of Nephrology</i> , 2017, 30, 677-687. | 0.9 | 56 |
| 760 | Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series. <i>Osteoporosis International</i> , 2017, 28, 2439-2444. | 1.3 | 9 |
| 761 | Medication management after intramedullary nailing of atypical fractures. <i>Injury</i> , 2017, 48, S15-S17. | 0.7 | 7 |
| 762 | Non-BMD DXA measurements of the hip. <i>Bone</i> , 2017, 104, 73-83. | 1.4 | 7 |
| 763 | Screening for Atypical Femur Fractures Using Extended Femur Scans by DXA. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1632-1639. | 3.1 | 35 |
| 764 | Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2111-2111. | 1.8 | 3 |
| 765 | Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteopenia. <i>Pharmacological Reports</i> , 2017, 69, 1113-1119. | 1.5 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 766 | Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2074-2086. | 3.1 | 55 |
| 767 | <sup />Composite Biomaterial as a Carrier for Bone-Active Substances for Metaphyseal Tibial Bone Defect Reconstruction in Rats. <i>Tissue Engineering - Part A</i> , 2017, 23, 1403-1412. | 1.6 | 23 |
| 768 | Factors affecting fracture location in atypical femoral fractures: A cross-sectional study with 147 patients. <i>Injury</i> , 2017, 48, 1570-1574. | 0.7 | 41 |
| 769 | Bisphosphonates and atypical subtrochanteric fractures of the femur. <i>Bone and Joint Research</i> , 2017, 6, 144-153. | 1.3 | 33 |
| 770 | Healing of Atypical Subtrochanteric Femur Fractures After Cephalomedullary Nailing: Which Factors Predict Union?. <i>Journal of Orthopaedic Trauma</i> , 2017, 31, 138-145. | 0.7 | 44 |
| 771 | Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis. <i>Scientific Reports</i> , 2017, 7, 46322. | 1.6 | 39 |
| 772 | Bilateral atypical femur fractures without bisphosphonate exposure. <i>Skeletal Radiology</i> , 2017, 46, 241-247. | 1.2 | 10 |
| 773 | Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. <i>Breast Cancer</i> , 2017, 24, 601-607. | 1.3 | 20 |
| 774 | Antiresorptives: Safety Concernsâ€”Clinical Perspective. <i>Toxicologic Pathology</i> , 2017, 45, 859-863. | 0.9 | 12 |
| 775 | T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture. <i>Journal of Bone and Joint Surgery - Series A</i> , 2017, 99, 1683-1688. | 1.4 | 8 |
| 776 | Evaluation of mandibular fracture healing in rats under zoledronate therapy: A histologic study. <i>Injury</i> , 2017, 48, 2683-2687. | 0.7 | 15 |
| 777 | Osteoclasts: Essentials and Methods. <i>Learning Materials in Biosciences</i> , 2017, , 33-53. | 0.2 | 1 |
| 778 | Bilateral patellar fractures and increased cortical bone thickness associated with long-term oral alendronate treatment in a cat. <i>Journal of Feline Medicine and Surgery Open Reports</i> , 2017, 3, 205511691772713. | 0.1 | 8 |
| 779 | A Novel H2S-releasing Amino-Bisphosphonate which combines bone anti-catabolic and anabolic functions. <i>Scientific Reports</i> , 2017, 7, 11940. | 1.6 | 33 |
| 780 | The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment. <i>Journal of Orthopaedic Science</i> , 2017, 22, 946-950. | 0.5 | 4 |
| 781 | Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8722-8727. | 3.3 | 122 |
| 782 | Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8Åyearsâ€™ experience in a single center. <i>Osteoporosis International</i> , 2017, 28, 3251-3259. | 1.3 | 40 |
| 783 | Surgical outcomes of intramedullary nailing for diaphyseal atypical femur fractures: is it safe to modify a nail entry in bowed femur?. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2017, 137, 1515-1522. | 1.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 784 | Atypical subtrochanteric fractures in Korean hip fracture study. <i>Osteoporosis International</i> , 2017, 28, 2853-2858. | 1.3 | 15 |
| 785 | Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. <i>Osteoporosis International</i> , 2017, 28, 2495-2503. | 1.3 | 5 |
| 786 | Outcomes between older adults with atypical and typical femoral fractures are comparable. <i>Injury</i> , 2017, 48, 394-398. | 0.7 | 10 |
| 788 | If prevention is better than cure, is nothing better than prevention?. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 99-102. | 1.3 | 0 |
| 789 | PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology. <i>Journal of Orthopaedic Research</i> , 2017, 35, 1707-1715. | 1.2 | 3 |
| 790 | Anterolateral femoral bowing and loss of thigh muscle are associated with occurrence of atypical femoral fracture: Effect of failed tension band mechanism in mid-thigh. <i>Journal of Orthopaedic Science</i> , 2017, 22, 99-104. | 0.5 | 17 |
| 791 | Effects of combined treatment with ibandronate and pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats. <i>Bioelectromagnetics</i> , 2017, 38, 31-40. | 0.9 | 37 |
| 792 | Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 536-548. | 3.1 | 9 |
| 793 | Double Fixation: Bilateral Bisphosphonate-Related Hip Fractures. <i>American Journal of Medicine</i> , 2017, 130, e13-e15. | 0.6 | 5 |
| 794 | Repeated oral administration of a cathepsin K inhibitor significantly suppresses bone resorption in exercising horses with evidence of increased bone formation and maintained bone turnover. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 327-334. | 0.6 | 6 |
| 796 | The Incidence of Atypical Femoral Fractures in Patients with Rheumatic Disease: Yamagata Prefectural Committee of Atypical Femoral Fractures (YamaCAFe) Study. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 242, 327-334. | 0.5 | 15 |
| 797 | Sanguinarine protects against ovariectomy-induced osteoporosis in mice. <i>Molecular Medicine Reports</i> , 2017, 16, 288-294. | 1.1 | 2 |
| 798 | Idiopathic Osteonecrosis and Atypical Femoral Fracture in Systemic Lupus Erythematosus. , 2017, , . | | 0 |
| 800 | Treatment of Atypical Ulnar Fractures Associated with Long-Term Bisphosphonate Therapy for Osteoporosis: Autogenous Bone Graft with Internal Fixation. <i>Case Reports in Orthopedics</i> , 2017, 2017, 1-4. | 0.1 | 15 |
| 801 | Atypical Femoral Shaft Fractures in Female Bisphosphonate Users Were Associated with an Increased Anterolateral Femoral Bow and a Thicker Lateral Cortex: A Case-Control Study. <i>BioMed Research International</i> , 2017, 2017, 1-10. | 0.9 | 13 |
| 802 | Bone Formation Parameters of the Biopsied Ilium Differ between Subtrochanteric and Diaphyseal Atypical Femoral Fractures in Bisphosphonate-Treated Patients. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 243, 247-254. | 0.5 | 8 |
| 803 | Long-term use of bisphosphonates in osteoporosis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2017, 38, 604-608. | 0.5 | 18 |
| 804 | Acetabular Insufficiency Fracture Following Prolonged Alendronate Use and the Failure of Total Hip Arthroplasty in "Frozen" Bone: Two Cases Report. <i>Hip and Pelvis</i> , 2017, 29, 286. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 805 | Lateral Femoral Bowing and the Location of Atypical Femoral Fractures. <i>Hip and Pelvis</i> , 2017, 29, 127-132. | 0.6 | 31 |
| 806 | EFFECT OF ALENDRONATE ON THE HEALING TIME OF DISTAL RADIAL FRACTURES TREATED CONSERVATIVELY: AN OBSERVATIONAL STUDY. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 168. | 0.3 | 1 |
| 807 | Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties. <i>Current Osteoporosis Reports</i> , 2018, 16, 198-204. | 1.5 | 20 |
| 808 | Fractures in the Elderly. , 2018, , . | | 1 |
| 809 | A proposal for an atypical femur fracture treatment and prevention clinical practice guideline. <i>Osteoporosis International</i> , 2018, 29, 1277-1283. | 1.3 | 23 |
| 810 | The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases. <i>JBMR Plus</i> , 2018, 2, 187-194. | 1.3 | 6 |
| 811 | MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. <i>European Journal of Endocrinology</i> , 2018, 178, R81-R87. | 1.9 | 27 |
| 812 | Atypical fractures: An issue of concern or a myth?. <i>Injury</i> , 2018, 49, 649-655. | 0.7 | 12 |
| 813 | A review of atypical subtrochanteric femoral fractures in Northern Ireland between 2010 and 2014. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2018, 28, 607-613. | 0.6 | 6 |
| 814 | A History of Pivotal Advances in Clinical Research into Bone and Mineral Diseases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 5-12. | 3.1 | 5 |
| 815 | Stress and Insufficiency Fractures. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2018, 16, 3-15. | 1.3 | 1 |
| 816 | IL-20 bone diseases involvement and therapeutic target potential. <i>Journal of Biomedical Science</i> , 2018, 25, 38. | 2.6 | 10 |
| 817 | Healing of fractures in osteoporotic bones in mice treated with bisphosphonates – A transcriptome analysis. <i>Bone</i> , 2018, 112, 107-119. | 1.4 | 24 |
| 818 | Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review. <i>JBMR Plus</i> , 2018, 2, 1-11. | 1.3 | 58 |
| 819 | Rare case of atypical femoral fracture with blocked medullary canal associated with bisphosphonate therapy. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2018, 9, S8-S11. | 0.6 | 3 |
| 820 | <i>in vivo</i> visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212880. | 0.5 | 16 |
| 821 | Bone histomorphometry in the evaluation of osteomalacia. <i>Bone Reports</i> , 2018, 8, 125-134. | 0.2 | 50 |
| 822 | The Effect of Bisphosphonates on the Clinical and Radiographic Outcomes of Distal Radius Fractures in Women. <i>Journal of Hand Surgery</i> , 2018, 43, 115-122. | 0.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 823 | Atraumatic femoral neck fracture during bisphosphonate treatment: case report and review of the literature. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 881-885. | 1.4 | 2 |
| 824 | Fracture Healing. , 2018, , 45-74. | | 0 |
| 825 | Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. <i>Journal of Evidence-based Dental Practice</i> , 2018, 18, 142-152. | 0.7 | 11 |
| 826 | Atypical Fracture of the Ulna Associated with 3 Years of Bisphosphonate Medication. <i>The Journal of the Korean Orthopaedic Association</i> , 2018, 53, 277. | 0.0 | 0 |
| 827 | Does Simultaneous Computed Tomography and Quantitative Computed Tomography Show Better Prescription Rate than Dual-energy X-ray Absorptiometry for Osteoporotic Hip Fracture?. <i>Hip and Pelvis</i> , 2018, 30, 233. | 0.6 | 2 |
| 828 | A Case Series and Discussion on Surgical Treatment Strategy for Atypical Proximal Femoral Fractures Associated with Bisphosphonate Use. <i>Cureus</i> , 2018, 10, e3670. | 0.2 | 5 |
| 829 | Salvage of failed osteosynthesis for an atypical subtrochanteric femoral fracture associated with long-term bisphosphonate treatment using a 95° angled blade plate. <i>Bone and Joint Journal</i> , 2018, 100-B, 1511-1517. | 1.9 | 13 |
| 830 | Outcomes for Elderly Patients With Atypical Femoral Fractures Compared to Typical Femoral Fractures for Length of Stay, Discharge Destination, and 30-Day Mortality Rate. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2018, 9, 215145931882022. | 0.6 | 4 |
| 831 | Hip Fracture Nonunions: Diagnosis, Treatment, and Special Considerations in Elderly Patients. <i>Advances in Orthopedics</i> , 2018, 2018, 1-11. | 0.4 | 14 |
| 832 | Atypical fractures and molecular environment: What do we know?. <i>Injury</i> , 2018, 49, 1953-1958. | 0.7 | 6 |
| 833 | Atypical Femoral Fractures: What Do We Know about Them?. <i>Journal of the Korean Fracture Society</i> , 2018, 31, 159. | 0.1 | 2 |
| 834 | Frequency and associated factor of atypical periprosthetic femoral fracture after hip arthroplasty. <i>Injury</i> , 2018, 49, 2264-2268. | 0.7 | 19 |
| 835 | ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy (GACI). <i>DMM Disease Models and Mechanisms</i> , 2018, 11, . | 1.2 | 23 |
| 836 | Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. <i>Current Osteoporosis Reports</i> , 2018, 16, 519-529. | 1.5 | 92 |
| 837 | Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. <i>Osteoporosis International</i> , 2018, 29, 2427-2435. | 1.3 | 36 |
| 838 | Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2498-2509. | 1.8 | 66 |
| 839 | Does zoledronate therapy make mandibular bone susceptible to fracture? A radiographical and biomechanical study in rats. <i>Injury</i> , 2018, 49, 1746-1749. | 0.7 | 1 |
| 840 | Hormone therapy for the treatment of postmenopausal osteoporosis: will it soon become a lost art in medicine?. <i>Menopause</i> , 2018, 25, 723-727. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 841 | The Role of Vitamin D in Orthopedic Surgery. , 2018, , 1043-1061. | | 1 |
| 842 | Polyphenols (S3) Isolated from Cone Scales of Pinus koraiensis Alleviate Decreased Bone Formation in Rat under Simulated Microgravity. Scientific Reports, 2018, 8, 12719. | 1.6 | 16 |
| 843 | The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration. Osteoporosis International, 2018, 29, 2659-2665. | 1.3 | 28 |
| 844 | Accumulation of microdamage at complete and incomplete fracture sites in a patient with bilateral atypical femoral fractures on glucocorticoid and bisphosphonate therapy. Journal of Bone and Mineral Metabolism, 2019, 37, 206-211. | 1.3 | 4 |
| 845 | The Role of Lower-Limb Geometry in the Pathophysiology of Atypical Femoral Fracture. Current Osteoporosis Reports, 2019, 17, 281-290. | 1.5 | 19 |
| 846 | A Retrospective Review on Atypical Femoral Fracture: Operative Outcomes and the Risk Factors for Failure. Geriatric Orthopaedic Surgery and Rehabilitation, 2019, 10, 215145931986473. | 0.6 | 10 |
| 847 | High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Rheumatology International, 2019, 39, 1803-1810. | 1.5 | 7 |
| 848 | Medication-Related Osteonecrosis of the Jaws. Journal of the National Cancer Institute Monographs, 2019, 2019, . | 0.9 | 23 |
| 849 | Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy—a long-term radiological follow-up. Osteoporosis International, 2019, 30, 2417-2428. | 1.3 | 9 |
| 850 | MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice. IUBMB Life, 2019, 71, 1916-1928. | 1.5 | 25 |
| 851 | Biomodulation of an implant for enhanced bone-implant anchorage. Acta Biomaterialia, 2019, 96, 619-630. | 4.1 | 34 |
| 853 | Localization of Atypical Femoral Fracture on Straight and Bowed Femurs. Journal of Bone Metabolism, 2019, 26, 123. | 0.5 | 13 |
| 854 | Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer, 2019, 19, 980. | 1.1 | 38 |
| 855 | Synergistic Application of Platelet-Rich Fibrin and 1% Alendronate in Periodontal Bone Regeneration: A Meta-Analysis. BioMed Research International, 2019, 2019, 1-12. | 0.9 | 11 |
| 856 | Atypical femoral fracture in the setting of alendronate treatment for osteoporosis: a case report and literature review. Journal of Community Hospital Internal Medicine Perspectives, 2019, 9, 340-343. | 0.4 | 1 |
| 857 | Incomplete atypical femoral fractures after bisphosphonate use in postmenopausal women. Journal of Orthopaedic Surgery, 2019, 27, 230949901987526. | 0.4 | 2 |
| 858 | Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporosis International, 2019, 30, 2515-2520. | 1.3 | 21 |
| 859 | Potential bone fragility of mid-shaft atypical femoral fracture: Biomechanical analysis by a CT-based nonlinear finite element method. Injury, 2019, 50, 1876-1882. | 0.7 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 860 | Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. <i>BMJ Case Reports</i> , 2019, 12, e229366. | 0.2 | 12 |
| 861 | Catalpol promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/ β -catenin pathway. <i>Stem Cell Research and Therapy</i> , 2019, 10, 37. | 2.4 | 49 |
| 862 | Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 805-814. | 1.3 | 22 |
| 863 | Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. <i>Nefrologia</i> , 2019, 39, 227-242. | 0.2 | 11 |
| 864 | Image-based anatomical reconstruction and pharmaco-mediated bone remodeling model applied to a femur with subtrochanteric fracture: A subject-specific finite element study. <i>Medical Engineering and Physics</i> , 2019, 69, 58-71. | 0.8 | 6 |
| 865 | CT bone density analysis of low-impact proximal femur fractures using Hounsfield units. <i>Clinical Imaging</i> , 2019, 57, 15-20. | 0.8 | 14 |
| 866 | A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture. <i>Calcified Tissue International</i> , 2019, 105, 51-67. | 1.5 | 16 |
| 867 | Microfiber-Reinforced Composite Hydrogels Loaded with Rat Adipose-Derived Stem Cells and BMP-2 for the Treatment of Medication-Related Osteonecrosis of the Jaw in a Rat Model. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 2430-2443. | 2.6 | 10 |
| 868 | Inhibition of macrophage viability by bound and free bisphosphonates. <i>Acta Histochemica</i> , 2019, 121, 400-406. | 0.9 | 10 |
| 869 | Bilateral subtrochanteric femur insufficiency fractures after bariatric surgery: a case report. <i>Osteoporosis International</i> , 2019, 30, 1317-1320. | 1.3 | 1 |
| 870 | Reliability and diagnostic utility of radiographs in patients with incomplete atypical femoral fractures. <i>Skeletal Radiology</i> , 2019, 48, 1427-1434. | 1.2 | 3 |
| 871 | Two Cases of Periprosthetic Atypical Femoral Fractures in Patients on Long-Term Bisphosphonate Treatment. <i>Case Reports in Surgery</i> , 2019, 2019, 1-6. | 0.2 | 10 |
| 872 | Preoperative bisphosphonate treatment may adversely affect the outcome after shoulder arthroplasty. <i>Bone and Joint Journal</i> , 2019, 101-B, 147-153. | 1.9 | 10 |
| 873 | A suspicious atypical fracture of 5th metatarsal bone: A case report. <i>Journal of Orthopaedic Science</i> , 2019, , . | 0.5 | 1 |
| 874 | Osteoporosis, densidad mineral \bar{A} sea y complejo CKD-MBD (II): implicaciones terap \bar{A} uticas. <i>Nefrologia</i> , 2019, 39, 227-242. | 0.2 | 24 |
| 875 | Clinical pathologies of bone fracture modelled in zebrafish. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, . | 1.2 | 27 |
| 876 | Effects of Intermittent Administration of Parathyroid Hormone and Parathyroid Hormone-Related Protein on Fracture Healing: A Narrative Review of Animal and Human Studies. <i>JBMR Plus</i> , 2019, 3, e10250. | 1.3 | 17 |
| 877 | Atypical incomplete femoral neck fracture in patients taking long-term bisphosphonate. <i>Medicine (United States)</i> , 2019, 98, e14701. | 0.4 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 878 | Detection and management of atypical femur fractures. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 283-290. | 1.2 | 5 |
| 879 | Nonunions of Bisphosphonate Fractures of the Femur: Presentation, Etiopathogenesis, Diagnosis, and Operative Treatment. <i>Journal of Orthopaedic Trauma</i> , 2019, 33, S14-S20. | 0.7 | 6 |
| 880 | Spatiotemporal Control Strategies for Bone Formation through Tissue Engineering and Regenerative Medicine Approaches. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801044. | 3.9 | 20 |
| 881 | Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice. <i>Nutrients</i> , 2019, 11, 63. | 1.7 | 8 |
| 882 | Cortical bone mineral density is increased by the cathepsin K inhibitor ONO-5334, which leads to a robust increase in bone strength: results from a 16-month study in ovariectomised cynomolgus monkeys. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 636-647. | 1.3 | 5 |
| 883 | Prevalence and Characteristics of Atypical Periprosthetic Femoral Fractures. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 83-92. | 3.1 | 24 |
| 884 | Cortical Bone Material Strength Index and Bone Microarchitecture in Postmenopausal Women With Atypical Femoral Fractures. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 75-82. | 3.1 | 34 |
| 885 | Adjuvant drug-assisted bone healing: Part III – Further strategies for local and systemic modulation. <i>Clinical Hemorheology and Microcirculation</i> , 2020, 73, 439-488. | 0.9 | 7 |
| 886 | Clinical Pharmacology of Bisphosphonates. , 2020, , 579-589. | | 1 |
| 887 | Atypical Femoral Fracture Associated With Overuse of Bisphosphonate Evaluated by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT). <i>Journal of Clinical Densitometry</i> , 2020, 23, 329-334. | 0.5 | 2 |
| 888 | Atypical femoral fracture associated with delayed union for which the cessation of alendronate and daily administration of teriparatide contributed to fracture healing: histopathological evidence of the enhancement in bone formation parameters. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 141-146. | 0.3 | 3 |
| 889 | Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. <i>Surgery</i> , 2020, 167, 144-148. | 1.0 | 18 |
| 890 | Surgical results of atypical femoral fractures in long-term bisphosphonate and glucocorticoid users – Relationship between fracture reduction and bone union. <i>Journal of Orthopaedics</i> , 2020, 19, 143-149. | 0.6 | 8 |
| 891 | Importance and Difficulty of Differentiating BMA-induced AFF Prodromal Symptoms from Hormonal Therapy-related Femoral Pain. <i>Internal Medicine</i> , 2020, 59, 855-857. | 0.3 | 1 |
| 893 | Bisphosphonate-related atypical femoral fractures: A novel strategy to improve patient outcomes. <i>Journal of Orthopaedics, Trauma and Rehabilitation</i> , 2020, 27, 192-197. | 0.1 | 2 |
| 894 | Early detected femoral neck insufficiency fracture in a patient treated with long-term bisphosphonate therapy for osteoporosis: A need for MRI. <i>International Journal of Surgery Case Reports</i> , 2020, 70, 213-215. | 0.2 | 3 |
| 895 | Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report. <i>Journal of Bone Oncology</i> , 2020, 23, 100301. | 1.0 | 9 |
| 896 | Diaphyseal femoral fracture due to severe vitamin D3 deficiency and low parathyroid hormone levels on long-term hemodialysis: a case report. <i>Archives of Osteoporosis</i> , 2020, 15, 179. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 897 | Treatment strategy for atypical ulnar fracture due to severely suppressed bone turnover caused by long-term bisphosphonate therapy: a case report and literature review. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 802. | 0.8 | 9 |
| 898 | Implementation of Endogenous and Exogenous Mesenchymal Progenitor Cells for Skeletal Tissue Regeneration and Repair. <i>Bioengineering</i> , 2020, 7, 86. | 1.6 | 9 |
| 899 | Inevitable nonunion after ulnar shortening osteotomy in patients with ulnar impaction syndrome and breast cancer under bisphosphonate treatment. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2020, 140, 1567-1574. | 1.3 | 2 |
| 901 | Atypical femur fractures: current understanding and approach to management. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091698. | 1.2 | 16 |
| 902 | Bilateral subtrochanteric insufficiency fracture following mini-gastric bypass. A case report. <i>Sicot-j</i> , 2020, 6, 32. | 0.8 | 0 |
| 903 | Bone Morphogenetic Protein-2 in Development and Bone Homeostasis. <i>Journal of Developmental Biology</i> , 2020, 8, 19. | 0.9 | 134 |
| 904 | Intramedullary Nail Fixation with Autologous Bone Marrow Transplantation in an Incomplete Atypical Femoral Fracture Patient: Use of Bone Marrow Extracted from the Hollow Reamer. <i>Case Reports in Orthopedics</i> , 2020, 2020, 1-4. | 0.1 | 1 |
| 905 | Bilateral atypical ulnar fractures occurring after long-term treatment with bisphosphonate for 7 years and with teriparatide for 2 years: a case report. <i>Osteoporosis International</i> , 2020, 31, 2473-2476. | 1.3 | 7 |
| 906 | Is Femoral Fracture Healing Really Compromised in Patients with Rheumatoid Arthritis? Comparison Study Between Rheumatoid and Non-rheumatoid Arthritis Patients. <i>Indian Journal of Orthopaedics</i> , 2020, 54, 599-607. | 0.5 | 0 |
| 907 | Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. <i>New England Journal of Medicine</i> , 2020, 383, 743-753. | 13.9 | 201 |
| 908 | Reference Intervals for Bone Histomorphometric Measurements Based on Data from Healthy Premenopausal Women. <i>Calcified Tissue International</i> , 2020, 107, 543-550. | 1.5 | 6 |
| 909 | Atypical periprosthetic femoral fractures of the hip: characterisation of three cases. <i>HIP International</i> , 2020, 30, 77-85. | 0.9 | 4 |
| 910 | Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database. <i>Pharmaceuticals</i> , 2020, 13, 467. | 1.7 | 17 |
| 911 | Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 801. | 0.8 | 6 |
| 912 | The Influence of Demographic Factors on the Location of Bisphosphonate-related Atypical Femoral Fractures. <i>Indian Journal of Orthopaedics</i> , 2020, 54, 116-120. | 0.5 | 1 |
| 913 | Synergistic use of biomaterials and licensed therapeutics to manipulate bone remodelling and promote non-union fracture repair. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 212-233. | 6.6 | 19 |
| 914 | Biological activity is not suppressed in mid-shaft stress fracture of the bowed femoral shaft unlike in atypical atypical subtrochanteric femoral fracture: A proposed theory of atypical femoral fracture subtypes. <i>Bone</i> , 2020, 137, 115453. | 1.4 | 24 |
| 915 | The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1180-1189. | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 916 | Fifty years of bisphosphonates: What are their mechanical effects on bone?. Bone, 2020, 138, 115518. | 1.4 | 13 |
| 917 | Management of Subtrochanteric Femoral Fracture Nonunions. JBJS Reviews, 2020, 8, e19.00143-e19.00143. | 0.8 | 8 |
| 918 | Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. Current Medicinal Chemistry, 2020, 27, 1151-1169. | 1.2 | 18 |
| 920 | Increased rate of reoperation in atypical femoral fractures is related to patient characteristics and not fracture type. A nationwide cohort study. Osteoporosis International, 2020, 31, 951-959. | 1.3 | 6 |
| 921 | A scorecard for osteoporosis in Canada and seven Canadian provinces. Osteoporosis International, 2021, 32, 123-132. | 1.3 | 9 |
| 922 | Evaluation of factors affecting the occurrence of second atypical fracture after bone union of the first atypical fracture. Bone, 2021, 143, 115671. | 1.4 | 1 |
| 923 | Outcome of revision surgery for bisphosphonate related subtrochanteric fracture non-union following failed intramedullary nailing. Injury, 2021, 52, 582-588. | 0.7 | 10 |
| 924 | Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study. Bone, 2021, 143, 115650. | 1.4 | 18 |
| 925 | Geranylgeraniol reverses alendronate-induced MC3T3 cell cytotoxicity and alteration of osteoblast function via cell cytoskeletal maintenance. Journal of Oral Pathology and Medicine, 2021, 50, 191-199. | 1.4 | 5 |
| 926 | Periprosthetic Fracture Resembling Atypical Femoral Fracture After Fixation With Retrograde Intramedullary Nail in Elderly Women: A Report of Two Cases. In Vivo, 2021, 35, 1837-1842. | 0.6 | 1 |
| 927 | Estrogen and estrogen analogs for prevention and treatment of osteoporosis. , 2021, , 1711-1719. | | 3 |
| 928 | Bone and primary hyperparathyroidism. Joint Bone Spine, 2022, 89, 105129. | 0.8 | 8 |
| 929 | Bisphosphonate: An Invaluable Medication or Abandoned Acid?. Journal of the Korean Fracture Society, 2021, 34, 122. | 0.1 | 0 |
| 930 | Disorders of Mineral Metabolism II. Abnormalities of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent. , 2021, , 705-813. | | 4 |
| 931 | Bisphosphonate-related atypical insufficiency fracture of the tibial plateau...: A case report. Journal of Medical Investigation, 2021, 68, 186-188. | 0.2 | 2 |
| 932 | Should denosumab treatment for osteoporosis be continued indefinitely?. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110100. | 1.4 | 7 |
| 933 | Evaluation and management of atypical femoral fractures: an update of current knowledge. European Journal of Orthopaedic Surgery and Traumatology, 2021, 31, 825-840. | 0.6 | 7 |
| 934 | Deep neural networks with promising diagnostic accuracy for the classification of atypical femoral fractures. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 394-400. | 1.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 935 | A comparison of alendronate to varying magnitude PEMF in mitigating bone loss and altering bone remodeling in skeletally mature osteoporotic rats. <i>Bone</i> , 2021, 143, 115761. | 1.4 | 13 |
| 936 | Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?. <i>Current Osteoporosis Reports</i> , 2021, 19, 182-188. | 1.5 | 7 |
| 937 | Valgus osteotomy for atypical interprosthetic femoral fracture with lateral bowing of the femur. <i>Trauma Case Reports</i> , 2021, 31, 100381. | 0.2 | 3 |
| 938 | Treatment with an active vitamin D analogue blocks hypothalamic dysfunction-induced bone loss in mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 542, 48-53. | 1.0 | 2 |
| 939 | Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1031-1041. | 3.1 | 9 |
| 940 | The Genetics of Atypical Femur Fractures—A Systematic Review. <i>Current Osteoporosis Reports</i> , 2021, 19, 123-130. | 1.5 | 15 |
| 941 | Os et hyperparathyroïdie primaire. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 110-119. | 0.0 | 0 |
| 943 | Histopathological Finding of Microdamage Accumulation in Atypical Subtrochanteric Femoral Fracture. <i>Case Reports in Orthopedics</i> , 2021, 2021, 1-6. | 0.1 | 0 |
| 944 | Bisphosphonates in Kidney Disease—Safety First. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 817-819. | 3.1 | 2 |
| 945 | A cautionary case: osteoporotic femur fracture after robotic-assisted total knee arthroplasty. <i>Osteoporosis International</i> , 2021, 32, 2125-2129. | 1.3 | 5 |
| 946 | Differences in subtrochanteric and diaphyseal atypical femoral fractures in a super-aging prefectural area: YamaCAFe Study. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 700-711. | 1.3 | 1 |
| 947 | Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy. <i>Osteoporosis International</i> , 2021, 32, 2119-2123. | 1.3 | 2 |
| 948 | Bisphosphonates impair the onset of bone formation at remodeling sites. <i>Bone</i> , 2021, 145, 115850. | 1.4 | 31 |
| 949 | Evaluation of the Nature and Etiologies of Risk Factors for Diaphyseal Atypical Femoral Fractures. <i>Medical Principles and Practice</i> , 2021, 30, 430-436. | 1.1 | 2 |
| 950 | Stress Fracture of the Femoral Shaft in Paget's Disease of Bone: A Case Report. <i>Journal of Bone Metabolism</i> , 2021, 28, 171-178. | 0.5 | 1 |
| 951 | Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. <i>Journal of General Internal Medicine</i> , 2022, 37, 1917-1924. | 1.3 | 5 |
| 952 | Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2541. | 1.0 | 4 |
| 953 | Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 193-203. | 1.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 954 | Disturbance of osteonal bone remodeling and high tensile stresses on the lateral cortex in atypical femoral fracture after long-term treatment with Risedronate and Alfacalcidol for osteoporosis. <i>Bone Reports</i> , 2021, 14, 101091. | 0.2 | 6 |
| 955 | The effects of alendronate on the suppression of bone resorption and the promotion of cartilage formation in the human mosaicplasty donor site: A randomized, double-blind, placebo-controlled prospective study. <i>Journal of Orthopaedic Science</i> , 2021, , . | 0.5 | 0 |
| 956 | Atypical periprosthetic femoral fractures after arthroplasty for fracture are at high risk of complications. <i>Scientific Reports</i> , 2021, 11, 14378. | 1.6 | 3 |
| 958 | Timing of geranylgeraniol addition increases osteoblast activities under alendronate condition. <i>Journal of Oral Biology and Craniofacial Research</i> , 2021, 11, 396-401. | 0.8 | 3 |
| 959 | Lower trabecular bone score is associated with an increased incidence of localized femoral periosteal thickening. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 952-961. | 1.3 | 1 |
| 960 | Hormone therapy for postmenopausal osteoporosis management. <i>Climacteric</i> , 2022, 25, 50-55. | 1.1 | 7 |
| 961 | The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 688269. | 1.5 | 15 |
| 962 | Bone Nanomechanical Properties and Relationship to Bone Turnover and Architecture in Patients With Atypical Femur Fractures: A Prospective Nested Caseâ€Control Study. <i>JBMR Plus</i> , 2021, 5, e10523. | 1.3 | 1 |
| 963 | Current concepts in the management of bisphosphonate associated atypical femoral fractures. <i>World Journal of Orthopedics</i> , 2021, 12, 660-671. | 0.8 | 3 |
| 964 | Multiple Porous Synthetic Bone Graft Comprising Engineered Micro-Channel for Drug Carrier and Bone Regeneration. <i>Materials</i> , 2021, 14, 5320. | 1.3 | 3 |
| 965 | Update on Osteoporosis Screening and Management. <i>Medical Clinics of North America</i> , 2021, 105, 1117-1134. | 1.1 | 79 |
| 966 | Intravenous bisphosphonate therapy does not delay fracture healing in inter-trochanteric femur fractures â€ A randomised controlled study. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2021, 20, 101472. | 0.6 | 6 |
| 967 | Diagnostic Criteria and Treatment of Atypical Ulnar Fractures Associated With Prolonged Bisphosphonate Therapy: Multicenter Case Analysis. <i>Journal of Hand Surgery</i> , 2022, 47, 901.e1-901.e12. | 0.7 | 6 |
| 968 | Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction. <i>Bone Research</i> , 2021, 9, 43. | 5.4 | 9 |
| 969 | Healthâ€related quality of life outcomes after surgical treatment of atypical femur fractures: a <sc>multicenter</sc> retrospective cohort study. <i>JBMR Plus</i> , 2021, 5, e10514. | 1.3 | 0 |
| 970 | Bone matrix quality in paired iliac bone biopsies from postmenopausal women treated for 12Âmonths with strontium ranelate or alendronate. <i>Bone</i> , 2021, 153, 116107. | 1.4 | 10 |
| 971 | A Novel Surgical Method for Treating Symptomatic Incomplete Atypical Femoral Fracture using Percutaneous Elastic Intramedullary Nailing. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2021, 12, 215145932110151. | 0.6 | 5 |
| 973 | Musculoskeletal Conditions. , 0, , 127-156. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 974 | Factors Contributing to Atypical Femoral Fractures. , 2016, , 125-136. | | 1 |
| 975 | Fracture Callus Under Anti-resorptive Agent Treatment Evaluated by pQCT. , 2007, , 553-566. | | 2 |
| 977 | Location of atypical femoral fracture can be determined by tensile stress distribution influenced by femoral bowing and neck-shaft angle: a CT-based nonlinear finite element analysis model for the assessment of femoral shaft loading stress. Injury, 2017, 48, 2736-2743. | 0.7 | 49 |
| 978 | Atypical diaphyseal femoral fractures: Considerations on surgical technique. Injury, 2019, 50, S65-S69. | 0.7 | 9 |
| 982 | Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review. Journal of Bone Metabolism, 2020, 27, 15. | 0.5 | 16 |
| 983 | Bilateral atypical femoral subtrochanteric fractures in a premenopausal patient receiving prolonged bisphosphonate therapy: evidence of severely suppressed bone turnover. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 273-7. | 1.0 | 11 |
| 984 | Atraumatic intracapsular neck of femur fractures after prolonged bisphosphonate treatment: a new atypical variant?. Clinical Cases in Mineral and Bone Metabolism, 2016, 13, 38-41. | 1.0 | 7 |
| 985 | Bisphosphonate Therapeutics in Bone Disease: The Hard and Soft Data on Osteoclast Inhibition. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2010, 10, 141-152. | 3.4 | 44 |
| 986 | Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture. BMJ Case Reports, 2014, 2014, bcr2013203519-bcr2013203519. | 0.2 | 5 |
| 987 | Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Reports, 2009, 2009, bcr1020081073-bcr1020081073. | 0.2 | 19 |
| 988 | Bisphosphonate therapy: To stop or not to stop?. BoneKEy Osteovision, 2007, 4, 78-82. | 0.6 | 3 |
| 989 | Bisphosphonate treatment and fracture repair. BoneKEy Osteovision, 2007, 4, 236-251. | 0.6 | 17 |
| 990 | Pathogenesis of osteonecrosis of the jaw. IBMS BoneKEy, 2008, 5, 69-77. | 0.1 | 2 |
| 991 | Periprosthetic bone loss: diagnostic and therapeutic approaches. F1000Research, 0, 2, 266. | 0.8 | 8 |
| 992 | Periprosthetic bone loss: diagnostic and therapeutic approaches. F1000Research, 2013, 2, 266. | 0.8 | 19 |
| 993 | Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. PLoS ONE, 2017, 12, e0184904. | 1.1 | 31 |
| 994 | Cerrahi olarak menopoz oluÅŸturulmuÅŸ sÄ±ÅŸanlarda melatonin tedavisinin Å†strojen, progesteron ve vitamin Dâ€™nin serum dÄ¼zeylerine etkisi. Ege TÄ±p Dergisi, 0, , 7-13. | 0.1 | 1 |
| 995 | Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis â€œ A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso). Archives of Endocrinology and Metabolism, 2020, ... | 0.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 997 | Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. <i>Clinical Interventions in Aging</i> , 2013, 8, 681. | 1.3 | 31 |
| 998 | Alendronate sodium in the management of osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 235-249. | 0.9 | 27 |
| 1000 | The Effect of Bisphosphonate on Bone Formation After Tooth Extraction in Ovariectomized Rats. <i>Journal of Hard Tissue Biology</i> , 2013, 22, 493-500. | 0.2 | 2 |
| 1001 | Therapeutic Advantages of Treatment of High-Dose Curcumin in the Ovariectomized Rat. <i>Journal of Korean Neurosurgical Society</i> , 2013, 54, 461. | 0.5 | 22 |
| 1002 | Spontaneous Non-Traumatic Stress Fractures in Bilateral Femoral Shafts in a Patient Treated with Bisphosphonates. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 98. | 0.7 | 6 |
| 1003 | Atraumatic Bilateral Femur Fracture in Long-Term Bisphosphonate Use. <i>Orthopedics</i> , 2009, 32, . | 0.5 | 39 |
| 1004 | Bilateral Simultaneous Femoral Diaphyseal Fractures in a Patient with Long-Term Ibandronate Use. <i>Orthopedics</i> , 2010, 33, 775. | 0.5 | 12 |
| 1005 | Atraumatic Bilateral Femur Fracture in Long-Term Bisphosphonate Use. <i>Orthopedics</i> , 2010, 33, 867-868. | 0.5 | 5 |
| 1006 | Bisphosphonate Fractures as a Cause of Painful Total Hip Arthroplasty. <i>Orthopedics</i> , 2011, 34, e939-44. | 0.5 | 33 |
| 1007 | Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy. <i>Acta Orthopaedica Et Traumatologica Turcica</i> , 2013, 47, 162-172. | 0.3 | 12 |
| 1008 | Osteonecrosis of the Jaw in a Patient with Osteoporosis Treated with Oral Bisphosphonates. <i>The Journal of the Korean Orthopaedic Association</i> , 2010, 45, 151. | 0.0 | 1 |
| 1009 | Epidemiology and Clinical Features of Atypical Femoral Fractures. <i>The Journal of the Korean Orthopaedic Association</i> , 2013, 48, 175. | 0.0 | 2 |
| 1010 | Surgical Treatment of Atypical Femoral Fracture. <i>The Journal of the Korean Orthopaedic Association</i> , 2013, 48, 185. | 0.0 | 2 |
| 1011 | Caveats of bisphosphonate abuse. <i>Indian Journal of Orthopaedics</i> , 2016, 50, 434. | 0.5 | 2 |
| 1012 | Therapeutic Dimensions of Bisphosphonates: A Clinical Update. <i>International Journal of Preventive Medicine</i> , 2020, 11, 166. | 0.2 | 9 |
| 1013 | The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis. <i>Asian Spine Journal</i> , 2015, 9, 338. | 0.8 | 5 |
| 1014 | The Effects of Low-Dose Bisphosphonate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Patients With Osteoporosis. <i>Annals of Geriatric Medicine and Research</i> , 2016, 20, 131-136. | 0.7 | 2 |
| 1015 | Dental extraction following zoledronate, induces osteonecrosis in rat's jaw. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2017, 22, 0-0. | 0.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1016 | Bisphosphonates in Orthopedics: Evidence-based Review of Indications and Adverse Effects. <i>Journal of Postgraduate Medicine Education and Research</i> , 2016, 50, 75-85. | 0.1 | 3 |
| 1017 | Orthopedic Implications of Bisphosphonate Therapy. <i>Orthopedics & Sports Medicine</i> , 2016, 44, 10-15. | 0.1 | 3 |
| 1018 | Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention. <i>Rambam Maimonides Medical Journal</i> , 2016, 7, e0032. | 0.4 | 9 |
| 1019 | Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use. <i>European Journal of Rheumatology</i> , 2016, 3, 87-90. | 1.3 | 10 |
| 1020 | Acute and long-term effects of corticosteroid therapy on bone metabolism in patients with kidney diseases. <i>Clinical Nephrology</i> , 2012, 78, 17-23. | 0.4 | 2 |
| 1021 | The Orthopaedic Implications of Diphosphonate Therapy. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2010, 18, 367-374. | 1.1 | 14 |
| 1022 | On the Horizon From the ORS. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2010, 18, 445-448. | 1.1 | 10 |
| 1023 | Current use of drugs for osteoporosis in Korea. <i>Korean Journal of Obstetrics and Gynecology</i> , 2010, 53, 152. | 0.1 | 10 |
| 1024 | Do atypical femoral fractures in patients with prolonged alendronate treatment heal?. <i>Eklemler Hastalıkları Ve Cerrahisi = Joint Diseases & Related Surgery</i> , 2014, 25, 52-55. | 2.5 | 2 |
| 1025 | Atypical femoral fracture following zoledronic acid treatment. <i>Eklemler Hastalıkları Ve Cerrahisi = Joint Diseases & Related Surgery</i> , 2016, 27, 54-57. | 2.5 | 4 |
| 1026 | A retrospective study of the healing process after tooth extraction in patients receiving oral bisphosphonates. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2011, 57, 658-665. | 0.0 | 1 |
| 1027 | Bisphosphonates and Osteonecrosis of the Jaw. <i>Annals of Internal Medicine</i> , 2006, 145, 791. | 2.0 | 6 |
| 1028 | Paradoxical Stress Fracture in a Patient With Multiple Myeloma and Bisphosphonate Use. <i>Cureus</i> , 2020, 12, e9837. | 0.2 | 3 |
| 1029 | Current concept of stress fractures with an additional category of atypical fractures: a perspective review with representative images. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110496. | 1.4 | 5 |
| 1030 | Long-term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4877-4879. | 1.1 | 3 |
| 1031 | Clinical and basic research papers – February 2005 selections. <i>BoneKEy Osteovision</i> , 2005, 2, 1-5. | 0.6 | 0 |
| 1032 | An Exploratory Analysis of Alendronate in Older Men with Low Glomerular Filtration Rate. <i>Journal of Aging and Pharmacotherapy</i> , 2006, 13, 21-33. | 0.0 | 0 |
| 1033 | Surgical Treatment of Fragility Fracture During Menopause. <i>Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association</i> , 2006, 49, 41. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1034 | Combination Therapy for Osteoporosis: What Do the Data Show Us?. , 2006, , 192-202. | | 0 |
| 1036 | A case of bisphosphonate-induced osteonecrosis of the mandible. Nihon Koku Geka Gakkai Zasshi, 2008, 54, 261-265. | 0.0 | 0 |
| 1037 | Biphosphonates in the Treatment of Bone Metastases – Osteonecrosis of the Jaw. Cancer Metastasis - Biology and Treatment, 2009, , 251-262. | 0.1 | 0 |
| 1038 | Physical and Chemical Injuries. , 2009, , 285-329. | | 1 |
| 1040 | Aspectos clínicos de la osteoporosis: actualización. Medwave, 2009, 9, . | 0.2 | 0 |
| 1041 | Bisphosphonates – Treatment of Osteoporosis. , 2010, , 469-486. | | 0 |
| 1042 | Zoledronic Acid Prevents Bone Loss in Premenopausal Women with Early Breast Cancer Undergoing Adjuvant Chemotherapy: A Phase III Study of Korean Cancer Study Group (KCSG-BR06-01).. , 2009, , . | | 0 |
| 1043 | Bilateral Femoral Subtrochanteric Insufficiency Fractures after Long-term Bisphosphonate Therapy. The Journal of the Korean Orthopaedic Association, 2010, 45, 146. | 0.0 | 2 |
| 1044 | Atypical Diaphyseal Femur Fractures in Patients with Prolonged Administration of Bisphosphonate Medication for Osteoporosis. Orthopedics, 2010, 33, 902-905. | 0.5 | 0 |
| 1045 | Anti-osteoporotic Drugs and Fracture Healing Mechanism. Journal of the Korean Fracture Society, 2011, 24, 212. | 0.1 | 2 |
| 1047 | Atraumatic Femoral Insufficiency Fracture in Postmenopausal Women Taking Bisphosphonate. The Showa University Journal of Medical Sciences, 2011, 23, 257-261. | 0.1 | 1 |
| 1050 | Putting Long-Term Adverse Events of Bisphosphonates into Perspective. Canadian Pharmacists Journal, 2011, 144, S13-S13.e1. | 0.4 | 0 |
| 1052 | Effects of 3 Years of Treatment with a Selective Estrogen Receptor Modulator for Postmenopausal Osteoporosis on Markers of Bone Turnover and Bone Mineral Density. The Showa University Journal of Medical Sciences, 2012, 24, 301-308. | 0.1 | 1 |
| 1053 | FRACTURE HEALING AND ANTIOSTEOPOROTIC TREATMENT. Osteoporosis and Bone Diseases, 2012, 15, 41-44. | 0.3 | 0 |
| 1054 | Bilateral Long Bone Fractures in a Patient with Sarcoid: A Case Report. Open Journal of Orthopedics, 2013, 03, 49-52. | 0.0 | 1 |
| 1056 | Bisphosphonate Related Atypical Femoral Fracture. Hip and Pelvis, 2013, 25, 66-71. | 0.6 | 1 |
| 1057 | ATYPICAL FRACTURES DUE TO LONG TREATMENT WITH BISPHOSPHONATES (CRITICAL REVIEW). TraumatologiĀ I OrtopediĀ Rossii, 2013, , 113-123. | 0.1 | 0 |
| 1058 | Femoral Shaft Cortical Pathology associated with long- term Alendronate Therapy: A New Classification. Malaysian Orthopaedic Journal, 2013, 7, 12-17. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1059 | Myeloma Bone Disease. , 2014, , 211-223. | | 0 |
| 1060 | Treatment and Prognosis of Femoral Insufficiency Fracture Associated with Prolonged Bisphosphonate Use. Journal of the Korean Fracture Society, 2014, 27, 10. | 0.1 | 1 |
| 1061 | Multi-level, bilateral pedicle fractures: case report. Turkish Neurosurgery, 2014, 25, 340-3. | 0.1 | 5 |
| 1062 | Management of the Patient Undergoing Radiotherapy or Chemotherapy. , 2014, , 363-381. | | 1 |
| 1063 | Improving Inter-Professional Communication among Medical and Dental Providers Treating Bisphosphonate Therapy Patients May Reduce the Risk of Osteonecrosis of the Jaw. Universal Journal of Clinical Medicine, 2014, 2, 35-42. | 0.3 | 0 |
| 1064 | PROPHYLACTIC INTRAMEDULLARY NAILING OF BISPHOSPHONATE RELATED BILATERAL SEQUENTIAL ATYPICAL FEMORAL SHAFT FRACTURE: A TREATMENT STRATEGY. Journal of Evolution of Medical and Dental Sciences, 2014, 3, 12023-12031. | 0.1 | 0 |
| 1065 | Are the Atypical Femoral Fractures a problem in order to Osteoporosis Treatment?: Its Management and Consequences. Rheumatology (Sunnyvale, Calif), 2015, 05, . | 0.3 | 0 |
| 1066 | A Case of Bisphosphonate-related Atypical Femoral Fracture with Bone Metastasis of Breast Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2015, 76, 2930-2934. | 0.0 | 0 |
| 1068 | Atypical Femoral Fractures: Pearls and Pitfalls. Journal of Osteoporosis and Physical Activity, 2015, 03, . | 0.2 | 0 |
| 1069 | Management of osteoporosis. , 2015, , 1663-1673. | | 1 |
| 1070 | Treatment and Prevention of Glucocorticoid-Induced Osteoporosis. , 2015, , 593-603. | | 0 |
| 1071 | Fractura simult nea de ambos f mures asociadas al consumo prolongado de Alendronato. Reporte de un caso. Revista De La Asociaci n Argentina De Ortopedia Y Traumatolog a, 2015, 80, 217. | 0.0 | 0 |
| 1072 | Recurrent Vertebral Compression Fracture while on Bisphosphonate Therapy    What is the Next Best Step in Management?. International Journal of Orthopedics and Rehabilitation, 2015, 2, 18-22. | 0.1 | 0 |
| 1073 | Bisphosphonate-Related Osteonecrosis of the Jaws: a real Challenge for Dentists. Acta Marisiensis - Seria Medica, 2015, 61, 115-119. | 0.3 | 1 |
| 1074 | Bilateral Simultaneous Femoral Fragility Fractures after Long - Term Alendronate Therapy. Journal of Islamic Academy of Sciences, 2016, 24, 20-23. | 0.0 | 0 |
| 1075 | Surgical or nonsurgical treatment of osteoporotic fractures. Journal of the Korean Medical Association, 2016, 59, 857. | 0.1 | 4 |
| 1076 | Clinical Presentation of Atypical Femur Fractures. , 2016, , 137-140. | | 1 |
| 1077 | Bilateral Spontaneous Bisphosphonate Insufficiency Fractures of the Proximal Tibia and Unilateral Distal Femur: A Case Report and Recommendation. MOJ Orthopedics & Rheumatology, 2016, 4, . | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1078 | Effects of Teriparatide Administration on Fracture Healing after Intramedullary Nailing in Atypical Femoral Fractures. The Journal of the Korean Orthopaedic Association, 2016, 51, 231. | 0.0 | 1 |
| 1079 | The Geometry of Lower Extremity and Atypical Femoral Fractures. , 2016, , 103-134. | | 0 |
| 1080 | Atypical femur fractures and use of bisphosphonates. Clinical Cases in Mineral and Bone Metabolism, 2016, 13, 204-208. | 1.0 | 7 |
| 1081 | The Bilateral Insufficiency Fracture of Proximal Femur due to Bisphosphonate Overuse in the Nonosteoporotic Bone. Journal of Clinical Case Reports, 2016, 06, . | 0.0 | 0 |
| 1082 | Biomarkers of Bisphosphonate Failure in Osteoporosis. Exposure and Health, 2016, , 1-21. | 2.8 | 0 |
| 1083 | The effects of Cudrania tricuspidata extract on bone metabolism in ovariectomized rats. International Journal of Industrial Entomology, 2016, 32, 80-89. | 0.1 | 0 |
| 1084 | Application of TLC-Densitometry for Analysis of Estradiol Hemihydrate in Dosage Forms.. Indian Journal of Pharmaceutical Education and Research, 2016, 50, 482-488. | 0.3 | 0 |
| 1087 | A Case of an Atypical Femoral Fracture Related to Long-term Use of Bisphosphonate for Bone Metastasis of Breast Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2017, 78, 21-25. | 0.0 | 1 |
| 1088 | Orthopedics & Traumatology, 2017, 66, 212-218. | 0.0 | 1 |
| 1089 | Bilateral Atypical Femoral Shaft Fractures and Bisphosphonate Therapy; A Case Report. MOJ Orthopedics & Rheumatology, 2017, 8, . | 0.2 | 0 |
| 1090 | BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAWS AND CURRENT THERAPIES. Cumhuriyet Dental Journal, 0, , 122-131. | 0.1 | 0 |
| 1091 | Role of bisphosphonates in treatment of osteoporosis in community. atypical periprosthetic sub trochanteric femur fractures during bisphosphonates therapy, a case report. International Journal of Family & Community Medicine, 2017, 1, . | 0.1 | 0 |
| 1092 | Bisphosphonate-induced Atypical Femoral Shaft Fracture; Cureus, 2017, 9, e1750. | 0.2 | 0 |
| 1093 | Simultaneous Bilateral Atypical Femoral Fracture: Case Presentation. MOJ Orthopedics & Rheumatology, 2017, 9, . | 0.2 | 0 |
| 1094 | Evaluation of Bone Fragility and Fracture Prevention. , 2018, , 285-301. | | 1 |
| 1095 | The Serum 25(OH)D Level in Patients with Atypical Femoral Fracture. Open Journal of Orthopedics, 2018, 08, 331-336. | 0.0 | 0 |
| 1096 | Cost-Effectiveness of Denosumab for Post-Menopausal Osteoporosis in South Korea. Korean Journal of Clinical Pharmacy, 2018, 28, 131-137. | 0.0 | 2 |
| 1097 | Bisphosphonates-induced Atypical Subtrochanteric Fracture Femur: A Case Report. Cureus, 2018, 10, e2937. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1137 | Bilateral atypical femoral fractures treated with compression hip screw and intramedullary nail fixation. <i>Trauma Case Reports</i> , 2022, 37, 100601. | 0.2 | 1 |
| 1138 | As fraturas associadas aos bifosfonatos demoram mais para cicatrizar?. <i>Brazilian Journal of Implantology and Health Sciences</i> , 2020, 2, 12-23. | 0.0 | 0 |
| 1140 | Comprehensive evaluation of adverse effects of host modulatory agents: A critical review. <i>Journal of the International Clinical Dental Research Organization</i> , 2021, 13, 93. | 0.0 | 0 |
| 1141 | Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study. <i>Modern Rheumatology</i> , 2021, , . | 0.9 | 0 |
| 1142 | Atypical Femoral Fracture in a Patient without Bisphosphonate or Denosumab Exposure-A Case Report. <i>Journal of Orthopaedic Case Reports</i> , 2021, 11, 21-24. | 0.1 | 0 |
| 1143 | Differences in femur geometry and bone markers in atypical femur fractures and the general population. <i>Scientific Reports</i> , 2021, 11, 24149. | 1.6 | 3 |
| 1144 | The Contribution of Deleterious Rare Alleles in ENPP1 and Osteomalacia Causative Genes to Atypical Femoral Fracture. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1890-e1898. | 1.8 | 5 |
| 1145 | Surveillance of atypical femoral fractures in a nationwide fracture register. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2022, 93, 229-233. | 1.2 | 3 |
| 1147 | Association of atypical femoral fracture location and lower limb mechanical axis: a computed tomography-based finite element analysis. <i>Osteoporosis International</i> , 2022, 33, 1285-1293. | 1.3 | 2 |
| 1148 | Ibandronate injections in postmenopausal women with osteoporosis. <i>Current Rheumatology Reports</i> , 2007, 9, 47; discussion 48-9. | 2.1 | 0 |
| 1149 | Incomplete Atypical Femoral Fracture Treated by Prophylactic Intramedullary Nail Fixation: A Case Series. <i>Cureus</i> , 2022, 14, e22725. | 0.2 | 0 |
| 1150 | Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects. <i>Frontiers in Pharmacology</i> , 2022, 13, 837534. | 1.6 | 13 |
| 1151 | Specific inflammatory osteoclast precursors induced during chronic inflammation give rise to highly active osteoclasts associated with inflammatory bone loss. <i>Bone Research</i> , 2022, 10, 36. | 5.4 | 15 |
| 1152 | Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database. <i>Pharmaceuticals</i> , 2021, 14, 1299. | 1.7 | 5 |
| 1153 | Surgical and Pharmacological Management of Periprosthetic Atypical Femoral Fractures: A Narrative Literature Review. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2022, 13, 215145932210903. | 0.6 | 1 |
| 1154 | ATYPICAL FEMORAL FRACTURES DUE TO THE USE OF BISPHOSPHONATES: EPIDEMIOLOGIC STUDY IN A TERTIARY HOSPITAL. <i>Acta Ortopedica Brasileira</i> , 2022, 30, . | 0.2 | 1 |
| 1157 | A case of incomplete atypical femoral fracture with histomorphometrical evidence of osteomalacia. <i>Acta Medica Okayama</i> , 2015, 69, 59-63. | 0.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1158 | Bone scintigraphy depicts bilateral atypical femoral stress fractures with metachronous presentation, long before a complete fracture occurs. <i>Hellenic Journal of Nuclear Medicine</i> , 2014, 17, 54-7. | 0.2 | 7 |
| 1160 | Atypical fracture of the femur in a patient with postmenopausal osteoporosis after four injections of zoledronic acid. <i>Russian Family Doctor</i> , 2022, 26, 27-32. | 0.1 | 0 |
| 1161 | Drugs for the skinternist. , 2013, , 408-423.e3. | | 0 |
| 1162 | Fragility Fractures of the Acetabulum: Current Concepts for Improving Patientsâ€™ Outcomes. <i>Indian Journal of Orthopaedics</i> , 0, , . | 0.5 | 1 |
| 1163 | Plate Fixation for Atypical Fractures of the Femoral Diaphysis. <i>Clinics in Orthopedic Surgery</i> , 2022, 14, 178. | 0.8 | 2 |
| 1164 | Bone regeneration: a message from clinical medicine and basic science. <i>Clinical Anatomy</i> , 0, , . | 1.5 | 2 |
| 1165 | Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model. <i>Nutrients</i> , 2022, 14, 2837. | 1.7 | 2 |
| 1166 | Musculoskeletal Injuries. , 2022, , 440-456. | | 0 |
| 1167 | Interest of Bone Histomorphometry in Bone Pathophysiology Investigation: Foundation, Present, and Future. <i>Frontiers in Endocrinology</i> , 0, 13, . | 1.5 | 8 |
| 1168 | Bisphosphonate-induced atypical femoral fracture in tandem: long-term follow-up is warranted. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, , . | 0.2 | 1 |
| 1169 | Duration and timing of bisphosphonate treatment as factors determining osteoblast mineralization. <i>Journal of Oral Biology and Craniofacial Research</i> , 2022, 12, 575-579. | 0.8 | 3 |
| 1170 | Atypical Fracture of Radial Diaphysis After SauvÃ©-Kapandji Procedure: A Retrospective Radiographic Evaluation of Fracture Progression. <i>Orthopedics</i> , 2023, 46, . | 0.5 | 1 |
| 1171 | Insufficiency Fracture of Simultaneously Bilateral Femur Neck in Patient Treated with Long-Term Bisphosphonate Treatment: A Case Report. <i>Journal of the Korean Fracture Society</i> , 2022, 35, 109. | 0.1 | 0 |
| 1172 | Discovery of Selective Covalent Cathepsin K Inhibitors Containing Novel 4-Cyanopyrimidine Warhead Based on Quantum Chemical Calculations and Binding Mode Analysis. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 1173 | Inhibition of Neddylation Suppresses Osteoclast Differentiation and Function In Vitro and Alleviates Osteoporosis In Vivo. <i>Biomedicines</i> , 2022, 10, 2355. | 1.4 | 3 |
| 1174 | Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101780. | 1.4 | 15 |
| 1175 | Atypical femoral fracture after long-term use of bisphosphonates: case reports and review of the literature. , 2021, 1, 9-13. | | 0 |
| 1176 | Atypical Femoral Fracture (AFF). , 2022, , 111-134. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1177 | Bilateral Subtrochanteric Complete Atypical Femoral Fracture in a Patient With Rheumatoid Arthritis: A Case Report. <i>Cureus</i> , 2022, , . | 0.2 | 0 |
| 1178 | Romosozumab-aqgg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia. <i>Journal of the Endocrine Society</i> , 2022, 6, . | 0.1 | 2 |
| 1179 | Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 74, 117053. | 1.4 | 0 |
| 1180 | Anterior radial head dislocation secondary to atypical ulnar fracture with atypical femoral fracture: A case report and literature review. , 2022, , . | | 0 |
| 1182 | Antiresorptive drugs and the risk of femoral shaft fracture in men and women with osteoporosis: A cohort study using the National Database of Health Insurance Claims of Japan. <i>Journal of Epidemiology</i> , 2022, , . | 1.1 | 0 |
| 1183 | Atypical fractures of the ulna: Effect of bowing of the ulna on fracture location and occurrence. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2023, 109, 103492. | 0.9 | 0 |
| 1185 | Dual energy x-ray absorptiometry (DXA) extended femur scans to support opportunistic screening for incomplete atypical femoral fractures: A short term in-vivo precision study.. <i>Journal of Clinical Densitometry</i> , 2022, , . | 0.5 | 0 |
| 1186 | A brief review and clinical evidences of teriparatide therapy for atypical femoral fractures associated with long-term bisphosphonate treatment. <i>Frontiers in Surgery</i> , 0, 9, . | 0.6 | 1 |
| 1187 | Simultaneous Bilateral Insufficiency Femoral Fractures After Long-Term Alendronate Treatment: A Lesson Not Yet Learned. <i>Cureus</i> , 2023, , . | 0.2 | 0 |
| 1188 | Untreated Atypical Left Femoral Shaft Fracture: A Case Report of Its Complication. <i>International Journal of Clinical Research</i> , 2022, 3, 202-208. | 0.1 | 0 |
| 1189 | EFFECT OF BISPHOSPHONATES ON FRACTURE HEALING AMONG THE ELDERLY PEOPLE WITH INTERTROCHANTERIC FRACTURE. , 2023, , 56-57. | | 0 |
| 1190 | Intraoperative Dysrhythmias Cease After Venting During Intramedullary Nailing of an Impending Femur Fracture. <i>JBJS Case Connector</i> , 2023, 13, . | 0.1 | 0 |
| 1191 | Therapeutic strategy for atypical ulnar fracture in long use of bisphosphonate: A systematic review. <i>Journal of Orthopaedic Science</i> , 2023, , . | 0.5 | 0 |
| 1192 | Prevalence of Monogenic Bone Disorders in a Dutch Cohort of Atypical Femur Fracture Patients. <i>Journal of Bone and Mineral Research</i> , 2020, 38, 896-906. | 3.1 | 1 |
| 1193 | Examination of Risk Factors and Expression Patterns of Atypical Femoral Fractures Using a Spontaneous Report Database: A Retrospective Pharmacovigilance Study. <i>Pharmaceuticals</i> , 2023, 16, 626. | 1.7 | 1 |
| 1202 | Long-term and sequential treatment for osteoporosis. <i>Nature Reviews Endocrinology</i> , 2023, 19, 520-533. | 4.3 | 13 |
| 1215 | The role of vitamin D in orthopedic surgery. , 2024, , 831-853. | | 0 |